14,842 results on '"Tuberculosis, Pulmonary drug therapy"'
Search Results
2. Respiratory impairment after completion of TB treatment: a neglected but vitally important issue.
- Author
-
Nguyen LN, Phan PT, Jaramillo E, Dinh A, and Dinh-Xuan AT
- Subjects
- Humans, Tuberculosis drug therapy, Tuberculosis, Pulmonary drug therapy, Antitubercular Agents administration & dosage
- Published
- 2024
- Full Text
- View/download PDF
3. Lung function and health-related quality of life among adult patients following pulmonary TB treatment.
- Author
-
Zawedde J, Abelman R, Musisi E, Nyabigambo A, Sanyu I, Kaswabuli S, Byanyima P, Lewis E, Sessolo A, Lalitha R, Kiwanuka N, Crothers K, Worodria W, Davis JL, and Huang L
- Subjects
- Humans, Male, Female, Adult, Risk Factors, Surveys and Questionnaires, Prevalence, Young Adult, Lung physiopathology, Middle Aged, Antitubercular Agents administration & dosage, Smoking epidemiology, Cross-Sectional Studies, Multivariate Analysis, Quality of Life, Tuberculosis, Pulmonary drug therapy, Spirometry
- Abstract
OBJECTIVES Pulmonary TB (PTB) increases the risk of chronic lung complications, which are associated with increased morbidity and mortality. We determined the prevalence and predictors of post-TB lung disease and persistent symptoms in a resource-limited setting.METHODS Adults who completed PTB treatment underwent spirometry and completed the St. George's Respiratory Questionnaire (SGRQ), a questionnaire that assesses quality of life on symptom, activity, and impact. We performed multivariate analyses to calculate the X-adjusted prevalence ratio (PRadj ) of abnormal spirometry and identify associated risk factors.RESULTS Among the 162 participants, 89 (54.9%) were male. The median age was 32 years, and 65 (40.1%) had HIV. Overall, 65 participants (40.1%) had abnormal lung function, with spirometric restriction seen in 29.0%, obstruction in 4.9%, and a mixed pattern in 6.2%. Smoking (PRadj 1.88, 95% CI 1.11-3.16; P = 0.02) and female sex (PRadj 1.81, 95% Cl 1.15-2.84; P = 0.01) were independent risk factors for abnormal lung function. The median SGRQ scores were higher in participants with cavitation ( P < 0.001) or bilateral consolidation on initial chest X-ray ( P = 0.01). .CONCLUSIONS Lung function abnormalities, particularly spirometric restriction, are common in patients completing PTB treatment. Female sex and smoking status were associated with lung function abnormalities; therefore, additional studies to understand the underlying mechanistic pathways are warranted.- Published
- 2024
- Full Text
- View/download PDF
4. Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis.
- Author
-
Wallis RS, Sabi I, Lalashowi J, Bakuli A, Mapamba D, Olomi W, Siyame E, Ngaraguza B, Chimbe O, Charalambous S, Rachow A, Ivanova O, Zurba L, Myombe B, Kunambi R, Hoelscher M, Ntinginya N, and Churchyard G
- Subjects
- Humans, Male, Female, Adult, Prospective Studies, Middle Aged, Lung drug effects, Lung microbiology, Lung physiopathology, Sputum microbiology, Treatment Outcome, Respiratory Function Tests, Young Adult, Acetylcysteine administration & dosage, Acetylcysteine therapeutic use, Tuberculosis, Pulmonary drug therapy, Antitubercular Agents therapeutic use, Antitubercular Agents administration & dosage, Glutathione blood
- Abstract
Background: Tuberculosis remains a global health concern, and half of cured patients have permanent lung injury. N-acetylcysteine (NAC) has shown beneficial antimicrobial, antioxidant, and immunomodulatory effects in preclinical tuberculosis models. We examined its effects on tuberculosis treatment outcomes., Methods: This prospective, randomized, controlled trial nested within the TB SEQUEL cohort study enrolled 140 adults with moderate or far-advanced tuberculosis. Participants were randomly assigned 1:1 to standard therapy with or without 1200 mg of oral NAC twice daily for days 1 to 112. Clinical evaluations, sputum culture, and spirometry were performed at specified intervals through day 168, after which participants returned to the TB SEQUEL cohort. The primary outcome was culture conversion. Secondary outcomes included whole-blood glutathione levels and lung function., Results: Participants were predominantly young, male, and human immunodeficiency virus 1-negative and had heavy sputum Mycobacterium tuberculosis (MTB) infection burdens. NAC increased glutathione levels (NAC × day interaction, 8.48; 95% confidence interval [CI], 1.93 to 15.02) but did not increase stable culture conversion (hazard ratio, 0.84; 95% CI, 0.59 to 1.20; P=0.33). NAC treatment was associated with improved recovery of lung function (NAC × month, 0.49 [95% CI, 0.02 to 0.95] and 0.42 [95% CI, -0.06 to 0.91] for forced vital capacity and forced expiratory volume in the first second, respectively, as percentages of predicted values). The effects of NAC on lung function were greatest in participants with severe baseline lung impairment and appeared to persist beyond the period of NAC administration. Rates of serious or grade 3 to 4 nonserious adverse events did not differ between the groups., Conclusions: Despite increasing whole-blood glutathione levels, NAC did not affect eradication of MTB infection in adults with pulmonary tuberculosis that was moderate to far advanced. Secondary outcomes of lung function showed changes that merit further investigation. (Funded by TB SEQUEL grant 01KA1613 of the German Ministry for Education and Research, the Health Africa Project, and the German Center for Infection Research; ClinicalTrials.gov number, NCT03702738.).
- Published
- 2024
- Full Text
- View/download PDF
5. Anti-tuberculosis effect of microbiome therapeutic PMC205 in extensively drug-resistant pulmonary tuberculosis in vivo.
- Author
-
Seo H, Yoon Y, Kim S, Ghorbanian F, Tajdozian H, Jo S, Barman I, Lee S, Lee Y, Rahim MA, Hossain MS, Lee S, and Song HY
- Subjects
- Animals, Mice, Bacillus subtilis drug effects, Female, Autophagy drug effects, Mice, Inbred C57BL, Humans, Mycobacterium tuberculosis drug effects, Probiotics therapeutic use, Probiotics administration & dosage, Disease Models, Animal, Extensively Drug-Resistant Tuberculosis drug therapy, Extensively Drug-Resistant Tuberculosis microbiology, Antitubercular Agents therapeutic use, Antitubercular Agents pharmacology, Lung microbiology, Lung pathology, Microbiota drug effects, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary microbiology
- Abstract
Background: Tuberculosis is a highly contagious disease caused by Mycobacterium tuberculosis, and the increase in antibiotic resistance threatens humankind. Therefore, there is an urgent need to develop new anti-tuberculosis drugs that can overcome the limitations of existing drugs. Here, we report the anti-tuberculosis effect of microbiome therapeutic PMC205, a strain of Bacillus subtilis., Methods: The anti-tuberculosis activity of probiotics was evaluated in mouse models of lethal and latent pulmonary tuberculosis induced by high or low-dose infection of the extensively drug-resistant strain. Probiotics were administered by inhalation, and the burden of M. tuberculosis in the lungs, along with mortality and clinical observations, were monitored for 12 weeks and 8 months, respectively. For an in-depth understanding, analysis of the microbiome and inflammatory profile of the lung microenvironment and induction of autophagy in vitro were explored., Results: After inhalation administration of PMC205 for 3 months, the survival rate was 100%, unlike all deaths in the saline-treated group, and the burden of M. tuberculosis in the lungs was reduced by log 1.3 in the 8-month latent tuberculosis model. Moreover, PMC205 induced recovery of disrupted lung microflora, increased butyric acid, and suppressed excessive inflammation. It also promoted autophagy., Conclusions: These results confirm PMC205's anti-tuberculosis effect, suggesting that it can be developed as an adjuvant to current antibiotic therapy to solve the drug-resistant tuberculosis problem., (Copyright © 2024. Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
6. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
- Author
-
Cevik M, Thompson LC, Upton C, Rolla VC, Malahleha M, Mmbaga B, Ngubane N, Abu Bakar Z, Rassool M, Variava E, Dawson R, Staples S, Lalloo U, Louw C, Conradie F, Eristavi M, Samoilova A, Skornyakov SN, Ntinginya NE, Haraka F, Praygod G, Mayanja-Kizza H, Caoili J, Balanag V, Dalcolmo MP, McHugh T, Hunt R, Solanki P, Bateson A, Crook AM, Fabiane S, Timm J, Sun E, Spigelman M, Sloan DJ, and Gillespie SH
- Subjects
- Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Young Adult, Drug Therapy, Combination, Ethambutol therapeutic use, Isoniazid therapeutic use, Mycobacterium tuberculosis drug effects, Rifampin therapeutic use, Treatment Outcome, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Multidrug-Resistant microbiology, Antitubercular Agents therapeutic use, Antitubercular Agents adverse effects, Diarylquinolines therapeutic use, Moxifloxacin therapeutic use, Moxifloxacin administration & dosage, Nitroimidazoles therapeutic use, Nitroimidazoles adverse effects, Pyrazinamide therapeutic use, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary microbiology
- Abstract
Background: The current tuberculosis (TB) drug development pipeline is being re-populated with candidates, including nitroimidazoles such as pretomanid, that exhibit a potential to shorten TB therapy by exerting a bactericidal effect on non-replicating bacilli. Based on results from preclinical and early clinical studies, a four-drug combination of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide (BPaMZ) regimen was identified with treatment-shortening potential for both drug-susceptible (DS) and drug-resistant (DR) TB. This trial aimed to determine the safety and efficacy of BPaMZ. We compared 4 months of BPaMZ to the standard 6 months of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE) in DS-TB. 6 months of BPaMZ was assessed in DR-TB., Methods: SimpliciTB was a partially randomised, phase 2c, open-label, clinical trial, recruiting participants at 26 sites in eight countries. Participants aged 18 years or older with pulmonary TB who were sputum smear positive for acid-fast bacilli were eligible for enrolment. Participants with DS-TB had Mycobacterium tuberculosis with sensitivity to rifampicin and isoniazid. Participants with DR-TB had M tuberculosis with resistance to rifampicin, isoniazid, or both. Participants with DS-TB were randomly allocated in a 1:1 ratio, stratified by HIV status and cavitation on chest radiograph, using balanced block randomisation with a fixed block size of four. The primary efficacy endpoint was time to sputum culture-negative status by 8 weeks; the key secondary endpoint was unfavourable outcome at week 52. A non-inferiority margin of 12% was chosen for the key secondary outcome. Safety and tolerability outcomes are presented as descriptive analyses. The efficacy analysis population contained patients who received at least one dose of medication and who had efficacy data available and had no major protocol violations. The safety population contained patients who received at least one dose of medication. This study is registered with ClinicalTrials.gov (NCT03338621) and is completed., Findings: Between July 30, 2018, and March 2, 2020, 455 participants were enrolled and received at least one dose of study treatment. 324 (71%) participants were male and 131 (29%) participants were female. 303 participants with DS-TB were randomly assigned to 4 months of BPaMZ (n=150) or HRZE (n=153). In a modified intention-to-treat (mITT) analysis, by week 8, 122 (84%) of 145 and 70 (47%) of 148 participants were culture-negative on 4 months of BPaMZ and HRZE, respectively, with a hazard ratio for earlier negative status of 2·93 (95% CI 2·17-3·96; p<0·0001). Median time to negative culture (TTN) was 6 weeks (IQR 4-8) on 4 months of BPaMZ and 11 weeks (6-12) on HRZE. 86% of participants with DR-TB receiving 6 months of BPaMZ (n=152) reached culture-negative status by week 8, with a median TTN of 5 weeks (IQR 3-7). At week 52, 120 (83%) of 144, 134 (93%) of 144, and 111 (83%) of 133 on 4 months of BPaMZ, HRZE, and 6 months of BPaMZ had favourable outcomes, respectively. Despite bacteriological efficacy, 4 months of BPaMZ did not meet the non-inferiority margin for the key secondary endpoint in the pre-defined mITT population due to higher withdrawal rates for adverse hepatic events. Non-inferiority was demonstrated in the per-protocol population confirming the effect of withdrawals with 4 months of BPaMZ. At least one liver-related treatment-emergent adverse effect (TEAE) occurred among 45 (30%) participants on 4 months of BPaMZ, 38 (25%) on HRZE, and 33 (22%) on 6 months of BPaMZ. Serious liver-related TEAEs were reported by 20 participants overall; 11 (7%) among those on 4 months of BPaMZ, one (1%) on HRZE, and eight (5%) on 6 months of BPaMZ. The most common reasons for discontinuation of trial treatment were hepatotoxicity (ten participants [2%]), increased hepatic enzymes (nine participants [2%]), QTcF prolongation (three participants [1%]), and hypersensitivity (two participants [<1%])., Interpretation: For DS-TB, BPaMZ successfully met the primary efficacy endpoint of sputum culture conversion. The regimen did not meet the key secondary efficacy endpoint due to adverse events resulting in treatment withdrawal. Our study demonstrated the potential for treatment-shortening efficacy of the BPaMZ regimen for DS-TB and DR-TB, providing clinical validation of a murine model widely used to identify such regimens. It also highlights that novel, treatment-shortening TB treatment regimens require an acceptable toxicity and tolerability profile with minimal monitoring in low-resource and high-burden settings. The increased risk of unpredictable severe hepatic adverse events with 4 months of BPaMZ would be a considerable obstacle to implementation of this regimen in settings with high burdens of TB with limited infrastructure for close surveillance of liver biochemistry. Future research should focus on improving the preclinical and early clinical detection and mitigation of safety issues together and further efforts to optimise shorter treatments., Funding: TB Alliance., Competing Interests: Declaration of interests We declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
7. Exploring cytokine dynamics in tuberculosis: A comparative analysis of patients and controls with insights from three-week antituberculosis intervention.
- Author
-
Krivošová M, Dohál M, Mäsiarová S, Pršo K, Gondáš E, Murín R, Fraňová S, Porvazník I, Solovič I, and Mokrý J
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Case-Control Studies, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary blood, Tuberculosis, Pulmonary immunology, Tuberculosis drug therapy, Tuberculosis blood, Young Adult, Biomarkers blood, Aged, Cytokines blood, Antitubercular Agents therapeutic use, Antitubercular Agents administration & dosage
- Abstract
Despite developing new diagnostics, drugs, and vaccines, treating tuberculosis (TB) remains challenging. Monitoring inflammatory markers can contribute to more precise diagnostics of TB, identifying its active and latent forms, or monitoring its treatment success. We assessed alterations in plasma levels of 48 cytokines in 20 patients (17 males) with active pulmonary TB compared to age-matched healthy controls (n = 18). Blood samples were collected from individuals hospitalised with TB prior to commencing antibiotic therapy, after the first week, and following the third week. The majority of patients received treatment with a combination of four first-line antituberculosis drugs: rifampicin, isoniazid, ethambutol, and pyrazinamide. Plasmatic cytokine levels from patients three times and controls were analyzed using a Bio-Plex Pro Human Cytokine Screening Panel. The results showed significantly higher levels of 31 cytokines (p<0.05) than healthy controls. Three-week therapy duration showed significantly decreased levels of nine cytokines: interferon alpha-2 (IFN-α2), interleukin (IL) 1 alpha (IL-1α), IL-1 receptor antagonist (IL-1ra), IL-6, IL-10, IL-12 p40, IL-17, leukemia inhibitory factor (LIF), and tumor necrosis factor alpha (TNF-α). Out of these, only levels of IL-1α and IL-6 remained significantly elevated compared to controls. Moreover, we have found a negative correlation of 18 cytokine levels with BMI of the patients but no correlation with age. Our results showed a clinical potential for monitoring the levels of specific inflammatory markers after a short treatment duration. The reduction in cytokine levels throughout the course of therapy could indicate treatment success but should be confirmed in studies with more individuals involved and a longer observation period., Competing Interests: The authors have no conflicts of interest to declare., (Copyright: © 2024 Krivošová et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
8. Predicting hospitalization costs for pulmonary tuberculosis patients based on machine learning.
- Author
-
Fan S, Abulizi A, You Y, Huang C, Yimit Y, Li Q, Zou X, and Nijiati M
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Aged, Hospital Costs statistics & numerical data, Length of Stay economics, Young Adult, Machine Learning, Tuberculosis, Pulmonary economics, Tuberculosis, Pulmonary drug therapy, Hospitalization economics
- Abstract
Background: Pulmonary tuberculosis (PTB) is a prevalent chronic disease associated with a significant economic burden on patients. Using machine learning to predict hospitalization costs can allocate medical resources effectively and optimize the cost structure rationally, so as to control the hospitalization costs of patients better., Methods: This research analyzed data (2020-2022) from a Kashgar pulmonary hospital's information system, involving 9570 eligible PTB patients. SPSS 26.0 was used for multiple regression analysis, while Python 3.7 was used for random forest regression (RFR) and MLP. The training set included data from 2020 and 2021, while the test set included data from 2022. The models predicted seven various costs related to PTB patients, including diagnostic cost, medical service cost, material cost, treatment cost, drug cost, other cost, and total hospitalization cost. The model's predictive performance was evaluated using R-square (R
2 ), Root Mean Squared Error (RMSE), and Mean Absolute Error (MAE) metrics., Results: Among the 9570 PTB patients included in the study, the median and quartile of total hospitalization cost were 13,150.45 (9891.34, 19,648.48) yuan. Nine factors, including age, marital status, admission condition, length of hospital stay, initial treatment, presence of other diseases, transfer, drug resistance, and admission department, significantly influenced hospitalization costs for PTB patients. Overall, MLP demonstrated superior performance in most cost predictions, outperforming RFR and multiple regression; The performance of RFR is between MLP and multiple regression; The predictive performance of multiple regression is the lowest, but it shows the best results for Other costs., Conclusion: The MLP can effectively leverage patient information and accurately predict various hospitalization costs, achieving a rationalized structure of hospitalization costs by adjusting higher-cost inpatient items and balancing different cost categories. The insights of this predictive model also hold relevance for research in other medical conditions., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
9. Factors affecting the readiness for hospital discharge of initially treated pulmonary tuberculosis patients in China: a phenomenological study.
- Author
-
Wang J, Zhang Y, Rao Q, Liu C, Du H, Cao X, and Xi M
- Subjects
- Humans, Male, Female, China, Adult, Middle Aged, Motivation, Interviews as Topic, Health Knowledge, Attitudes, Practice, Aged, Tuberculosis, Pulmonary psychology, Tuberculosis, Pulmonary therapy, Tuberculosis, Pulmonary drug therapy, Patient Discharge, Qualitative Research
- Abstract
Background: Despite readiness for hospital discharge widespread popularity since readiness for hospital discharge introduction in 1979 and extensive study, readiness for hospital discharge among pulmonary tuberculosis (PTB) patients has not yet been investigated. Moreover, the factors influencing this process remain unclear., Objective: The objective of this study was to investigate the factors influencing readiness for hospital discharge in initially treated PTB patients using the capability, opportunity, motivation-behavior (COM-B) model., Methods: This phenomenological study was conducted from December 2023 to March 2024. Face-to-face individual interviews were conducted with 18 initially treated patients with PTB according to a semistructured interview guide developed on the basis of the COM-B model. The interview data were subjected to analysis using NVivo 14 software and Colaizzi's method., Results: As a result, 6 themes and 14 subthemes were identified. Physical capability for readiness for hospital discharge (subthemes included poor health status, early acquisition of adequate knowledge about PTB, inadequate knowledge about readiness for hospital discharge), psychological capability for readiness for hospital discharge(subthemes included false perceptions about readiness for hospital discharge, high treatment adherence), physical opportunity for readiness for hospital discharge (subthemes included high continuity of transition healthcare, insufficient financial support, insufficient informational support), social opportunity for readiness for hospital discharge (subthemes included stigmatization, inadequate emotional support), reflective motivation for readiness for hospital discharge (subthemes included lack of reflection on coping with difficulties, intention to develop a readiness for hospital discharge plan), and automatic motivation for readiness for hospital discharge (subthemes included strong desire to be cured, negative emotions)., Conclusion: We established factors related to readiness for hospital discharge in initially treated PTB patients in terms of capability, opportunity and motivation, which can inform the future development of readiness for hospital discharge plans. To improve patients' readiness for hospital discharge, patients need to be motivated to plan and desire readiness for hospital discharge, patients' knowledge and treatment adherence should be improved, and patients' transition healthcare continuity and emotional support should be focused on. Moreover, the quality of readiness for hospital discharge and discharge education should be assessed in a timely manner to identify impeding factors and provide interventions., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
10. Risk assessment and transmission of fluoroquinolone resistance in drug-resistant pulmonary tuberculosis: a retrospective genomic epidemiology study.
- Author
-
Nehru VJ, Jose Vandakunnel M, Brammacharry U, Ramachandra V, Pradhabane G, Mani BR, Vn AD, and Muthaiah M
- Subjects
- Humans, Retrospective Studies, Male, Female, Tuberculosis, Pulmonary epidemiology, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary microbiology, Adult, Mutation, Risk Assessment, Middle Aged, Microbial Sensitivity Tests, Rifampin pharmacology, Rifampin therapeutic use, Extensively Drug-Resistant Tuberculosis epidemiology, Extensively Drug-Resistant Tuberculosis microbiology, Extensively Drug-Resistant Tuberculosis drug therapy, Drug Resistance, Multiple, Bacterial genetics, Isoniazid pharmacology, Isoniazid therapeutic use, Aged, Fluoroquinolones pharmacology, Fluoroquinolones therapeutic use, Mycobacterium tuberculosis genetics, Mycobacterium tuberculosis drug effects, Tuberculosis, Multidrug-Resistant epidemiology, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Multidrug-Resistant microbiology, Tuberculosis, Multidrug-Resistant transmission, Tuberculosis, Multidrug-Resistant genetics, Antitubercular Agents pharmacology, Antitubercular Agents therapeutic use
- Abstract
Fluoroquinolone resistance is a major challenge in treating Multidrug-Resistant Tuberculosis globally. The GenoType MTBDRsl Ver 2.0, endorsed by the WHO, was used to characterize fluoroquinolone resistance. The fluoroquinolone resistance rates in the MDR-TB, Rifampicin-Resistant TB, and non-MDR-TB were 33%, 16.5%, and 5.4%, respectively. The most common mutation found in fluoroquinolone-resistant isolates was D94G (49.5%) in the gyrA gene. Of the 150 MDR-TB isolates, the prevalence of Extensively Drug-Resistant Tuberculosis and pre-XDR-TB was 1.33% and 30%, respectively. Among the 139 RR-TB isolates, pre-XDR-TB prevalence was 15.8%. The fluoroquinolone resistance rates were 5.12% among the 1230 isoniazid-monoresistant isolates. The study found that MDR-TB and RR-TB have higher risk of fluoroquinolone resistance than non-MDR tuberculosis. Rifampicin-resistant isolates with a mutation at codon S450L have a higher risk (RR = 12.96; 95%CI: 8.34-20.13) of developing fluoroquinolone resistance than isolates with mutations at other codons in the rpoB gene. Isoniazid-resistant isolates with a mutation at codon S315T have a higher risk (RR = 2.09; 95%CI: 1.25-3.50) of developing fluoroquinolone resistance. The study concludes that rapid diagnosis of fluoroquinolone resistance before starting treatment is urgently needed to prevent the spread and increase of resistance and to achieve better treatment outcomes in areas where it is higher., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
11. Exploring mean platelet volume and neutrophil-to-albumin ratio as surrogate markers for monitoring tuberculosis treatment: a prospective longitudinal study.
- Author
-
Rajakumar HK, Coimbatore Sathyabal V, Palaniyandi A, and Balakrishnan D
- Subjects
- Humans, Male, Female, Adult, Prospective Studies, Middle Aged, Longitudinal Studies, India, Sputum microbiology, Tuberculosis diagnosis, Tuberculosis blood, Tuberculosis drug therapy, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary blood, Tuberculosis, Pulmonary diagnosis, C-Reactive Protein analysis, Albumins analysis, Young Adult, Linear Models, Biomarkers blood, Antitubercular Agents therapeutic use, Mean Platelet Volume, Neutrophils
- Abstract
Background: Tuberculosis (TB) remains a global health challenge, with India bearing a significant burden. Despite advancements in TB diagnosis and treatment, monitoring TB treatment is challenging, particularly in resource-limited settings. This study aimed to explore the mean platelet volume (MPV) as a potential surrogate marker for monitoring TB treatment and assessing if the neutrophil-to-albumin ratio (NAR) enhances treatment monitoring., Methods: Patients diagnosed with TB following NTEP guidelines were recruited. Participants underwent routine blood tests during the six-month Anti-Tubercular therapy course at the start, end of the intensive phase, and end of the continuous phase. Statistical analyses included Spearman correlation, Friedman test, linear mixed effects (LME) models, and multiple linear regression., Results: 150 individuals were included for analysis. Deviations from normality were noted. Significant associations were found between CRP and sputum grade. MPV mediated between CRP and sputum grade. Significant differences were observed across the three-time points. LME models showed changes in MPV and CRP levels over time. Including NAR enhanced predictive capability., Conclusions: MPV may serve as a promising surrogate marker for monitoring ATT. Personalized approaches are crucial in TB treatment monitoring. LME models revealed MPV and CRP level trends. Future research should explore MPV's treatment response mechanisms and cost-effectiveness., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
12. Opportunistic infections among people living with HIV/AIDS attending antiretroviral therapy clinics in Gedeo Zone, Southern Ethiopia.
- Author
-
Gebremichael G, Tadele N, Gebremedhin KB, and Mengistu D
- Subjects
- Humans, Ethiopia epidemiology, Male, Adult, Female, Retrospective Studies, Prevalence, Middle Aged, Young Adult, Candidiasis, Oral epidemiology, Acquired Immunodeficiency Syndrome drug therapy, Acquired Immunodeficiency Syndrome epidemiology, Adolescent, Tuberculosis, Pulmonary epidemiology, Tuberculosis, Pulmonary drug therapy, CD4 Lymphocyte Count, Anti-HIV Agents therapeutic use, AIDS-Related Opportunistic Infections epidemiology, HIV Infections drug therapy, HIV Infections epidemiology
- Abstract
Introduction: Opportunistic infections (OIs) are more common and severe among people with suppressed immunity like those living with HIV/AIDS (PLWH). This study aimed to assess the prevalence of OIs and associated factors among PLWH attending antiretroviral therapy (ART) clinics in the Gedeo zone, Southern Ethiopia., Methods: A facility based retrospective cohort study was conducted from April to June 2018 among PLWH attending ART clinics in Gedeo zone, Ethiopia from November 2016 - November 2017. A simple random sampling method was used to select the both paper based and electronic study participants' charts. Adjusted odds ratios were calculated using multivariable logistic regression analysis for variables statistically significant at 95% confidence interval under bivariable logistic regression analysis, and significance was declared at P < 0.05., Results: a total of 266 PLWH attended the selected ART clinics of Gedeo zone during the one year period were participated in the current study. The majority 104(39.1%) were within the age group 30-39, 106(60.2%) male, 184(69.2%) married, and 167(62.9%) urban residents. The study revealed the prevalence of OIs was 113(42.5%) with oral candidiasis 28(24.5%) the most prevalent followed by pulmonary tuberculosis 22(19.5%) and herpes zoster 15(13.4%). Further, study participants with ambulatory [AOR = 2.40(95% CI: 1.14, 5.03)], and bedridden [AOR = 3.27(95% CI:1.64, 6.52)] working functional status; with lower CD4 count: less than 200cells/mm
3 [AOR = 9.14(95% CI: 2.75, 30.39)], 200-350cells/mm3 [AOR = 9.45(95% CI: 2.70,33.06)], 351-500cells/mm3 [AOR = 5.76(95% CI: 1.71, 19.39)]; being poor in ART adherence level [AOR = 10.05(95% CI: 4.31,23.46)]; being in stage III/IV WHO clinical stage of HIV/AIDS [AOR = 2.72(95% CI: 1.42, 5.20)]; and being chewing khat [AOR = 2.84(95% CI: 1.21, 6.65)] were found positively predicting the occurrence of OIs., Conclusion: This study speckled a high prevalence of OIs with several predicting factors. Therefore, the study acmes there should be interventional means which tackles the higher prevalence of OIs with focus to the predicting factors like lower CD4 count level, less/bedridden working functional status, poor ART adherence level, advanced stage of HIV/AIDS stage and chewing khat., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
13. Association of Fine Particulate Matter and Residential Greenness With Risk of Pulmonary Tuberculosis Retreatment: Population-Based Retrospective Study.
- Author
-
Guo T, Shen F, Xin H, Du J, Cao X, Feng B, He Y, Shen L, Di Y, Chen Y, Li Z, Jin Q, Li H, Zhang C, and Gao L
- Subjects
- Humans, Retrospective Studies, Middle Aged, Female, Male, China epidemiology, Adult, Air Pollution adverse effects, Air Pollution analysis, Environmental Exposure adverse effects, Environmental Exposure statistics & numerical data, Retreatment statistics & numerical data, Aged, Risk Factors, Residence Characteristics statistics & numerical data, Particulate Matter analysis, Particulate Matter adverse effects, Tuberculosis, Pulmonary epidemiology, Tuberculosis, Pulmonary drug therapy
- Abstract
Background: The evidence on the association of fine particulate matter with an aerodynamic diameter of 2.5 μm or less (PM2.5) with pulmonary tuberculosis (PTB) retreatment is limited. There are no data on whether greenness exposure protects air pollution-related PTB retreatment in patients with prior PTB., Objective: In a population-based retrospective study, we aimed to investigate the influence of PM2.5 and residential greenness on the risk of PTB retreatment., Methods: A total of 26,482 patients with incident PTB, registered in a mandatory web-based reporting system between 2012 and 2019 in Zhengzhou, China, were included in the analysis. The exposure to PM2.5 was assessed based on the China High Air Pollutants dataset, and the level of greenness was estimated using the Normalized Difference Vegetation Index (NDVI) values. The associations of PTB retreatment with exposure to PM2.5 and greenness were evaluated, respectively, considering the local socioeconomic level indicated by the nighttime light index., Results: Among the 26,482 patients (mean age 46.86, SD 19.52 years) with a median follow-up time of 1523 days per patient, 1542 (5.82%) PTB retreatments were observed between 2012 and 2019. Exposure to PM2.5 was observed to be significantly associated with the increased risk of PTB retreatment in fully adjusted models with a hazard ratio of 1.97 (95% CI 1.34-2.83) per 10 μg/m3 increase in PM2.5. Patients living in the regions with relatively high quartiles of NDVI values had a 45% lower risk of PTB retreatment than those living in the regions with the lowest quartile for the 500 m buffers (hazard ratio 0.55, 95% CI 0.40-0.77). Such a protective effect of residential greenness was more pronounced among patients living in lower nighttime light areas. The strength of the association between PM2.5 exposure and the risk of PTB retreatment was attenuated by greenness. No significant association was observed between NDVI and the incidence of drug resistance., Conclusions: Long-term exposure to PM2.5 might be a risk factor for PTB retreatment, while an increased level of residential greenness was found to be associated with reduced risks of PTB retreatment. Our results suggest strengthening the control of ambient air pollution and improving residential greenness may contribute to the reduction of PTB retreatment., (© Tonglei Guo, Fei Shen, Henan Xin, Jiang Du, Xuefang Cao, Boxuan Feng, Yijun He, Lingyu Shen, Yuanzhi Di, Yanxiao Chen, Zihan Li, Qi Jin, Hongzhi Li, Chunming Zhang, Lei Gao. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org).)
- Published
- 2024
- Full Text
- View/download PDF
14. Impact of serum chitotriosidase activity on tuberculosis treatment response: single center study from Serbia.
- Author
-
Adzic-Vukicevic T, Stosic M, Sumarac Z, Cvetkovic A, Markovic O, and Maric D
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Aged, Longitudinal Studies, Serbia, Logistic Models, Treatment Outcome, Biomarkers blood, Multivariate Analysis, Mycobacterium tuberculosis isolation & purification, Hexosaminidases blood, Antitubercular Agents therapeutic use, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary blood, Sputum microbiology
- Abstract
Background: The aim of our study was to investigate serum chitotriosidase level in tuberculosis patients, its relationship with microbiological and clinical parameters, and response to treatment., Materials and Methods: This longitudinal panel study included 149 patients with confirmed TB disease. Serum chitotriosidase activity was measured at the beginning and the end of treatment. Factors associated with chitotriosidase activity were explored using univariate and multivariable logistic regression analysis., Results: Out of 149 study participants, 71(47.7%) were female. The mean age was 53.0 (SD = 18.2). Majority of cases were new 118(79.2), predominantly 145 (97.3%) having pulmonary tuberculosis. More than half of the patients were sputum smear positive 91 (61.1%) while culture positive in 146 (98%) of them. According to radiological findings, cavitary lesions were found in 92 (63.4%) patients. Anti TB treatment was associated with significant decrease in serum chitotriosidase level (< 0.001). New TB treatment (OR = 4.41%;95% CI = 1.20-9.89), and cavitary lesions (OR = 3.86;95%CI = 0,59-26.57) were found to be significantly associated with decrease of chitotriosidase activity., Conclusions: The results of our study showed that serum chitotriosidase values are strong biomarkers for starting anti TB treatment and for treatment monitoring, since decrease in serum chitotriosidase level can predict favorable treatment response in patients with tuberculosis. Further studies are needed to explore these, and other factors associated with chitotriosidase activity among tuberculosis patients., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
15. A study on factors influencing delayed sputum conversion in newly diagnosed pulmonary tuberculosis based on bacteriology and genomics.
- Author
-
Pang M, Dai X, Wang N, Yi J, Sun S, Miao H, Zhang J, Zhang H, Li J, Ding B, Yang X, and Li C
- Subjects
- Humans, Male, Adult, Female, Retrospective Studies, Middle Aged, Polymorphism, Single Nucleotide, Microbial Sensitivity Tests, Whole Genome Sequencing, Treatment Outcome, Drug Resistance, Bacterial genetics, Tuberculosis, Pulmonary microbiology, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary diagnosis, Sputum microbiology, Mycobacterium tuberculosis genetics, Mycobacterium tuberculosis isolation & purification, Mycobacterium tuberculosis drug effects, Antitubercular Agents therapeutic use, Antitubercular Agents pharmacology, Genomics methods
- Abstract
Conversion of sputum from positive to negative is one of the indicators to evaluate the efficacy of anti-tuberculosis treatment (ATT). We investigate the factors associated with delayed sputum conversion after 2 or 5 months of ATT from the perspectives of bacteriology and genomics. A retrospective study of sputum conversion in sputum positive 1782 pulmonary tuberculosis (PTB) was conducted from 2021 to 2022 in Beijing, China. We also designed a case-matched study including 24 pairs of delayed-sputum-conversion patients (DSCPs) and timely-sputum-conversion patients (TSCPs), and collect clinical isolates from DSCPs before and after ATT and initial isolates of TSCPs who successfully achieved sputum conversion to negative after 2 months of ATT. A total of 75 strains were conducted drug sensitivity testing (DST) of 13 anti-TB drugs and whole-genome sequencing (WGS) to analyze the risk factors of delayed conversion and the dynamics changes of drug resistance and genomics of Mycobacterium tuberculosis (MTB) during ATT. We found TSCPs have better treatment outcomes and whose initial isolates show lower levels of drug resistance. Clinical isolates of DSCPs showed dynamically changing of resistance phenotypes and intra-host heterogeneity. Single nucleotide polymorphism (SNP) profiles showed large differences between groups. The study provided insight into the bacteriological and genomic variation of delayed sputum conversion. It would be helpful for early indication of sputum conversion and guidance on ATT., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
16. Breaking the Cycle: Matrix Metalloproteinase Inhibitors as an Alternative Approach in Managing Tuberculosis Pathogenesis and Progression.
- Author
-
Jhilta A, Jadhav K, Singh R, Ray E, Kumar A, Singh AK, and Verma RK
- Subjects
- Humans, Antitubercular Agents pharmacology, Antitubercular Agents therapeutic use, Animals, Tuberculosis, Pulmonary drug therapy, Tuberculosis drug therapy, Disease Progression, Matrix Metalloproteinase Inhibitors pharmacology, Matrix Metalloproteinase Inhibitors therapeutic use, Mycobacterium tuberculosis drug effects, Matrix Metalloproteinases metabolism
- Abstract
Mycobacterium tuberculosis (Mtb) has long posed a significant challenge to global public health, resulting in approximately 1.6 million deaths annually. Pulmonary tuberculosis (TB) instigated by Mtb is characterized by extensive lung tissue damage, leading to lesions and dissemination within the tissue matrix. Matrix metalloproteinases (MMPs) exhibit endopeptidase activity, contributing to inflammatory tissue damage and, consequently, morbidity and mortality in TB patients. MMP activities in TB are intricately regulated by various components, including cytokines, chemokines, cell receptors, and growth factors, through intracellular signaling pathways. Primarily, Mtb-infected macrophages induce MMP expression, disrupting the balance between MMPs and tissue inhibitors of metalloproteinases (TIMPs), thereby impairing extracellular matrix (ECM) deposition in the lungs. Recent research underscores the significance of immunomodulatory factors in MMP secretion and granuloma formation during Mtb pathogenesis. Several studies have investigated both the activation and inhibition of MMPs using endogenous MMP inhibitors (i.e., TIMPs) and synthetic inhibitors. However, despite their promising pharmacological potential, few MMP inhibitors have been explored for TB treatment as host-directed therapy. Scientists are exploring novel strategies to enhance TB therapeutic regimens by suppressing MMP activity to mitigate Mtb-associated matrix destruction and reduce TB induced lung inflammation. These strategies include the use of MMP inhibitor molecules alone or in combination with anti-TB drugs. Additionally, there is growing interest in developing novel formulations containing MMP inhibitors or MMP-responsive drug delivery systems to suppress MMPs and release drugs at specific target sites. This review summarizes MMPs' expression and regulation in TB, their role in immune response, and the potential of MMP inhibitors as effective therapeutic targets to alleviate TB immunopathology.
- Published
- 2024
- Full Text
- View/download PDF
17. Tongue Tuberculosis as a Complication of Pott's Disease in a Patient on Systemic Steroid Therapy without Pulmonary Tuberculosis.
- Author
-
Sevilla-Fuentes S, Mendoza-Vargas LÁ, Araiza-Rodríguez JF, Berthaúd-González B, Falfán-Valencia R, and Bautista-Becerril B
- Subjects
- Humans, Male, Aged, Tongue Diseases etiology, Tongue Diseases drug therapy, Tuberculosis, Oral drug therapy, Arthritis, Rheumatoid complications, Arthritis, Rheumatoid drug therapy, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary complications, Adrenal Cortex Hormones therapeutic use, Magnetic Resonance Imaging, Tuberculosis, Spinal complications, Tuberculosis, Spinal drug therapy
- Abstract
A 78-year-old man with a previous diagnosis of rheumatoid arthritis on prolonged treatment with corticosteroids presented with intense and progressive pain at the cervical level that prevented him from resting his head and walking, in addition to an ulcerative lesion covering 80% of the lingual area that was previously treated as oral candidiasis without improvement. On arrival, with no clinical or serological data of rheumatoid arthritis, immunosuppressive treatment was suspended, and a biopsy of the oral cavity was requested, confirming the diagnosis of lingual tuberculosis, an extremely rare disease, occurring in less than 1% of extrapulmonary cases. MRI of the cervical spine showed a crush fracture of the C6 and C7 bodies associated with spondylitis of probably infectious etiology that required surgical treatment, and histopathological studies confirmed Pott's disease. The patient displayed no evidence of pulmonary tuberculosis from arrival until the end of the follow-up.
- Published
- 2024
- Full Text
- View/download PDF
18. Recurrent Pulmonary Tuberculosis in China, 2005 to 2021.
- Author
-
Li T, Zhang B, Du X, Pei S, Jia Z, and Zhao Y
- Subjects
- Humans, China epidemiology, Male, Female, Retrospective Studies, Middle Aged, Adult, Aged, Young Adult, Risk Factors, Adolescent, Aged, 80 and over, Tuberculosis, Pulmonary epidemiology, Tuberculosis, Pulmonary drug therapy, Recurrence
- Abstract
Importance: Despite posing a significant challenge to global tuberculosis (TB) elimination efforts, recurrent TB remains understudied due to the challenges of long-term observation., Objective: To investigate the burden of recurrent TB using data from patients with pulmonary TB (PTB) in China., Design, Setting, and Participants: This retrospective cohort study included all bacteriologically confirmed or clinically diagnosed PTB cases reported to the Tuberculosis Information Management System with completed or successful treatment outcomes from January 1, 2005, to December 31, 2021. Data were analyzed from July 15, 2022, to October 28, 2023., Exposures: Newly diagnosed PTB was classified into primary, hematogenous disseminated, or secondary PTB., Main Outcomes and Measures: The primary outcome was the annual recurrence rate, stratified by disease classification, over the 17-year observation period. The recurrence rate for year n was calculated by dividing the number of patients with recurrent TB in year n by observed person-years in year n. The secondary outcome was the annual proportion of recurrent TB among reported cases and associated risk factors., Results: Of 13 833 249 patients with TB reported to the Tuberculosis Information Management System, 10 482 271 with PTB met the inclusion criteria. Of these, 68.9% were male, 22.3% were 65 years or older, 89.6% were of Han ethnicity, and 68.4% were agricultural workers. A total of 413 936 patients experienced a recurrent TB episode after successful treatment, resulting in an overall recurrence rate of 0.47 (95% CI, 0.47-0.48) per 100 person-years. The recurrence rate for patients with primary PTB was 0.24 (95% CI, 0.22-0.26) per 100 person-years; for hematogenous disseminated PTB, 0.37 (95% CI, 0.36-0.38) per 100 person-years; and for secondary PTB, 0.48 (95% CI, 0.47-0.48) per 100 person-years. The cumulative proportion of recurrences within the first 2 years accounted for 48.9% of all recurrent cases. The proportion of recurrent cases among notified incident cases increased 1.9-fold from 4.7% in 2015 to 8.8% in 2021. Among other factors, ages 45 to 64 years (adjusted hazard ratio, 1.77 [95% CI, 1.65-1.89]) and having completed treatment (adjusted hazard ratio, 1.16 [95% CI, 1.14-1.18]) were identified as associated with recurrence., Conclusions and Relevance: In this retrospective cohort study, the PTB recurrence rate was substantially higher than the incidence, and the proportion of recurrent cases increased. Almost half of the recurrence occurred within the first 2 years, suggesting that routine posttreatment follow-up may represent an important strategy for accelerating TB elimination.
- Published
- 2024
- Full Text
- View/download PDF
19. Post-TB bronchiectasis: clinical characteristics and microbiology.
- Author
-
Hoole AS, Ilyas A, Munawar S, Cant M, Hameed R, Gill S, Riaz J, and Siddiq I
- Subjects
- Humans, Male, Female, Middle Aged, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary diagnosis, Retrospective Studies, Adult, Mycobacterium tuberculosis isolation & purification, Aged, Antitubercular Agents administration & dosage, Antitubercular Agents therapeutic use, Bronchiectasis microbiology
- Published
- 2024
- Full Text
- View/download PDF
20. Pulmonary tuberculosis in two preterm infants conceived by in vitro fertilization.
- Author
-
Wang Y, Yang J, Liu Y, Deng L, and Pan L
- Subjects
- Humans, Female, Infant, Newborn, Male, Antitubercular Agents therapeutic use, COVID-19 complications, COVID-19 diagnosis, Fertilization in Vitro, Tuberculosis, Pulmonary diagnosis, Tuberculosis, Pulmonary complications, Tuberculosis, Pulmonary drug therapy, Infant, Premature, Mycobacterium tuberculosis isolation & purification
- Abstract
The early diagnosis of tuberculosis (TB) in infants is challenging owing to the non-specific clinical manifestations in infancy, particularly preterm infants. Two cases in preterm infants are reported. Case 1, conceived by in vitro fertilization (IVF), was born at 27 + 1 weeks gestational age weighing 880 g. He presented on Day 85 with intermittent fever. Following a course of systemic broadspectrum antibiotics, he deteriorated, developing acute respiratory distress syndrome (ARDS). TB Xpert polymerase chain reaction (PCR) of the sputum obtained by laryngeal aspiration confirmed Mycobacterium TB (MTB) on Day 97. He responded well to anti-tuberculosis treatment. His mother had a fever and headache and was diagnosed with COVID-19 79 days after delivery. The fever persisted for nearly 10 days after empirical treatment. She was eventually diagnosed with miliary TB and tuberculous meningitis 92 days after delivery. Case 2 was conceived by IVF and born at 36 + 6 weeks gestation weighing 2430 g. She presented on Day 15 with intermittent fever and abdominal distention. Chest and abdominal radiography demonstrated severe diffuse inflammatory changes. She had received BCG vaccination, and there was no history of contact with active TB. TB PCR of the sputum obtained by laryngeal aspiration confirmed MTB on Day 19. The asymptomatic mother was subsequently diagnosed with pulmonary and genital TB. TB should be considered as a differential diagnosis in infants with unexpected respiratory distress and fever. Women evaluated for infertility should be routinely screened for TB before receiving assisted reproductive treatment, particularly where TB is prevalent. Abbreviations: ARDS: acute respiratory distress syndrome; BPD: bronchopulmonary dysplasia; CPAP: continuous positive airway pressure; CSF: cerebrospinal fluid; HIV: human immunodeficiency virus; IVF: in vitro fertilization; KMC: Kangaroo mother care; MDR: multidrug-resistant; MTB: Mycobacterium tuberculosis ; NICU: neonatal intensive care unit; PCR: polymerase chain reaction; PS: pulmonary surfactant; SIMV: synchronised intermittent mandatory ventilation; TB: tuberculosis; CT: computed tomography; HREZ: isoniazid, rifampin, ethambutol and pyrazinamide; IGRA: interferon-γ release assay; IVF: in vitro fertilization; PCR: polymerase chain reaction; TB: tuberculosis.
- Published
- 2024
- Full Text
- View/download PDF
21. The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs.
- Author
-
Wijk M, Gausi K, Malatesta S, Weber SE, Court R, Myers B, Carney T, Parry CDH, Horsburgh CR, White LF, Wiesner L, Warren RM, Uren C, McIlleron H, Kloprogge F, Denti P, and Jacobson KR
- Subjects
- Humans, Male, Adult, Female, South Africa, Middle Aged, Prospective Studies, Isoniazid pharmacokinetics, Alcohol Drinking adverse effects, Tuberculosis, Pulmonary drug therapy, Substance-Related Disorders, Pyrazinamide pharmacokinetics, Pyrazinamide administration & dosage, Ethambutol pharmacokinetics, Young Adult, Antitubercular Agents pharmacokinetics, Rifampin pharmacokinetics
- Abstract
Background: In South Africa, an estimated 11% of the population have high alcohol use, a major risk factor for TB. Alcohol and other substance use are also associated with poor treatment response, with a potential mechanism being altered TB drug pharmacokinetics., Objectives: To investigate the impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs in participants with pulmonary TB., Methods: We prospectively enrolled participants ≥15 years old, without HIV, and initiating drug-susceptible TB treatment in Worcester, South Africa. Alcohol use was measured via self-report and blood biomarkers. Other illicit substances were captured through a urine drug test. Plasma samples were drawn 1 month into treatment pre-dose, and 1.5, 3, 5 and 8 h post-dose. Non-linear mixed-effects modelling was used to describe the pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol. Alcohol and drug use were tested as covariates., Results: The study included 104 participants, of whom 70% were male, with a median age of 37 years (IQR 27-48). Alcohol use was high, with 42% and 28% of participants having moderate and high alcohol use, respectively. Rifampicin and isoniazid had slightly lower pharmacokinetics compared with previous reports, whereas pyrazinamide and ethambutol were consistent. No significant alcohol use effect was detected, other than 13% higher ethambutol clearance in participants with high alcohol use. Methaqualone use reduced rifampicin bioavailability by 19%., Conclusion: No clinically relevant effect of alcohol use was observed on the pharmacokinetics of first-line TB drugs, suggesting that poor treatment outcome is unlikely due to pharmacokinetic alterations. That methaqualone reduced rifampicin means dose adjustment may be beneficial., (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.)
- Published
- 2024
- Full Text
- View/download PDF
22. Post-tuberculosis Sequelae in Children.
- Author
-
Goyal R and Parakh A
- Subjects
- Humans, Child, Risk Factors, India, Tuberculosis, Pulmonary complications, Tuberculosis, Pulmonary drug therapy, Nervous System Diseases etiology, Tuberculosis complications, Tuberculosis drug therapy
- Abstract
Tuberculosis (TB) is a global health problem especially in the Indian subcontinent imposing significant physical, psychosocial and economic burden on the society. Most national programs define TB cure as completion of treatment with improvement in clinical symptoms, microbiological and radiological clearance. However, follow up these patients for long-term sequelae or complications has not got adequate attention. Post-TB lung disease, neurological deficits and spinal deformities are some of the post-TB sequelae reported in adults, with scanty data available for children. With this review authors attempt to discuss various post-TB disease manifestations and the risk factors associated with their development in children. They address the need to create awareness amongst physicians involved in managing children with TB and obtain more scientific data in this field., (© 2023. The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation.)
- Published
- 2024
- Full Text
- View/download PDF
23. Chest X-ray alone is insufficient for predicting drug-resistant pulmonary tuberculosis.
- Author
-
Skouvig Pedersen O, Butova T, Borovok N, Akymenko O, Sapelnik N, Tantsura O, Knysh V, Fløe A, Dahl VN, and Butov D
- Subjects
- Humans, Antitubercular Agents pharmacology, Antitubercular Agents therapeutic use, Mycobacterium tuberculosis drug effects, Mycobacterium tuberculosis genetics, Male, Middle Aged, Adult, Female, Tuberculosis, Multidrug-Resistant microbiology, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Multidrug-Resistant diagnosis, Tuberculosis, Pulmonary diagnostic imaging, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary microbiology, Radiography, Thoracic
- Published
- 2024
- Full Text
- View/download PDF
24. Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug Resistance.
- Author
-
de Vos M, David A, Duraisamy K, Nadarajan D, Noroc E, Penn-Nicholson A, Crudu V, Giri S, Maurer FP, Pati S, Stevens W, Scott L, Turuk J, Schumacher SG, and Ruhwald M
- Subjects
- Humans, South Africa, Adult, India, Tuberculosis, Pulmonary diagnosis, Tuberculosis, Pulmonary microbiology, Tuberculosis, Pulmonary drug therapy, Female, Antitubercular Agents pharmacology, Antitubercular Agents therapeutic use, Drug Resistance, Bacterial genetics, Whole Genome Sequencing methods, Male, Moldova, Molecular Diagnostic Techniques methods, Mycobacterium tuberculosis genetics, Mycobacterium tuberculosis drug effects, Rifampin pharmacology, Rifampin therapeutic use, Sensitivity and Specificity, Isoniazid pharmacology, Isoniazid therapeutic use, Tuberculosis, Multidrug-Resistant diagnosis, Tuberculosis, Multidrug-Resistant microbiology, Tuberculosis, Multidrug-Resistant drug therapy, Microbial Sensitivity Tests methods
- Abstract
This study evaluated the performance of cobas MTB and cobas MTB-RIF/INH for the diagnosis of tuberculosis and detection of rifampicin (RIF) and isoniazid (INH) resistance. Adults presenting with pulmonary tuberculosis symptoms were recruited in South Africa, Moldova, and India. Performance of cobas MTB was assessed against culture, whereas cobas MTB-RIF/INH was assessed using phenotypic drug susceptibility testing and whole-genome sequencing as composite reference standards. Xpert MTB/RIF (Xpert) or Xpert MTB/RIF Ultra (Ultra) was used as a comparator. The overall sensitivity and specificity of cobas MTB were 95% (95% CI, 93%-96%) and 96% (95% CI, 95%-97%). Among smear-negatives, the sensitivity of cobas MTB was 75% (95% CI, 66%-83%). Among participants tested with both cobas MTB and Xpert, sensitivity was 96% (95% CI, 94%-97%) for cobas MTB and 95% (95% CI, 93%-97%) for Xpert. Among participants tested with both cobas MTB and Ultra, sensitivity was 88% (95% CI, 81%-92%) for cobas MTB and 89% (95% CI, 83%-93%) for Ultra. Sensitivity and specificity of cobas MTB-RIF/INH for RIF and INH detection were 90% (95% CI, 84%-94%) and 100% (95% CI, 99%-100%), and 89% (95% CI, 84%-93%) and 99.5% (95% CI, 98%-100%), respectively. The cobas MTB and cobas MTB-RIF/INH assays exhibited high performance in a diverse population and present a suitable option for molecular detection of tuberculosis and RIF and INH resistance., Competing Interests: Disclosure Statement M.d.V., A.P.-N., A.M., S.O., P.N., and M.R. are employees of FIND. S.G.S., J.M., I.K., and A.P. were employed by FIND at the time of the study. S.S., S.S.C., and K.D. are employees of FIND, India. F.P.M. changed employment from Research Center Borstel (Borstel, Germany) to Roche (Rotkreuz, Switzerland) after the completion of the study in July 2022. (A.M., S.O., P.N., S.S., S.S.C., J.M., I.K., and A.P. are Study Group members.), (Copyright © 2024 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. Mitigating treatment failure of pulmonary pre-extensively drug-resistant tuberculosis: The role of new and repurposed drugs.
- Author
-
Huang YW, Yu MC, Lin CB, Lee JJ, Lin CJ, Chien ST, Lee CH, and Chiang CY
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Taiwan, Drug Repositioning, Extensively Drug-Resistant Tuberculosis drug therapy, Retrospective Studies, Aged, Drug Resistance, Multiple, Bacterial, Tuberculosis, Pulmonary drug therapy, Mycobacterium tuberculosis drug effects, Fluoroquinolones therapeutic use, Treatment Outcome, Antitubercular Agents therapeutic use, Treatment Failure, Tuberculosis, Multidrug-Resistant drug therapy
- Abstract
Background: Pre-extensively drug-resistant tuberculosis (pre-XDR-TB), defined as multidrug-resistant TB (MDR-TB) with additional resistance to any fluoroquinolone (FQ) is difficult to treat. We assessed whether the use of new or repurposed drugs (bedaquiline, delamanid, linezolid, carbapenem, clofazimine, pretomanid) mitigated treatment failure of pre-XDR-TB., Methods: MDR-TB patients managed in the Taiwan MDR-TB consortium between July 2009-December 2019 were eligible. Treatment outcomes at 30 months were assessed. Logistic regression models were constructed to investigate factors associated with treatment outcomes., Results: 109 patients with FQ-resistant MDR-TB and 218 patients with FQ-susceptible MDR-TB were included. 60 (55.1%) patients with FQ-resistant MDR-TB and 63 (28.9%) patients with FQ-susceptible MDR-TB have been treated with new or repurposed drugs (p < 0.01). Of the 218 patients with FQ-susceptible MDR-TB, 187 (85.8%) had treatment success, 30 (13.8%) died, no treatment failure, and 1 (0.5%) was loss-to-follow-up; of the 109 patients with FQ-resistant MDR-TB, 78 (71.6%) had treatment success, 21 (19.3%) died, 9 (8.3%) had treatment failure, and 1 (0.9%) was loss-to-follow-up (p < 0.01). The use of new or repurposed drugs was not associated with treatment outcomes among patients with FQ-susceptible MDR-TB. No patients with FQ-resistant MDR-TB treated with ≥2 new or repurposed drugs within 6 months of treatment initiation had treatment failure (p = 0.03). Patients with FQ-resistant MDR-TB treated with 1 new or repurposed drugs was more likely to have treatment failure as compared with patients not treated with new or repurposed drugs (adjOR 7.06, 95% CI 1.72-29.06)., Conclusions: Proper use of new or repurposed anti-TB drugs can mitigate treatment failure in FQ-resistant MDR-TB., Competing Interests: Declaration of competing interest None declared., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
26. Advances in an In Vitro Tuberculosis Infection Model Using Human Lung Organoids for Host-Directed Therapies.
- Author
-
Kim SY, Choi JA, Choi S, Kim KK, Song CH, and Kim EM
- Subjects
- Humans, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary microbiology, Macrophages microbiology, Tuberculosis drug therapy, Tuberculosis microbiology, Epithelial Cells microbiology, Organoids microbiology, Mycobacterium tuberculosis drug effects, Lung microbiology, Lung pathology, Antitubercular Agents pharmacology, Antitubercular Agents therapeutic use
- Abstract
The emergence of drug-resistant Mycobacterium tuberculosis (M.tb) has led to the development of novel anti-tuberculosis (anti-TB) drugs. Common methods for testing the efficacy of new drugs, including two-dimensional cell culture models or animal models, have several limitations. Therefore, an appropriate model representative of the human organism is required. Here, we developed an M.tb infection model using human lung organoids (hLOs) and demonstrated that M.tb H37Rv can infect lung epithelial cells and human macrophages (hMφs) in hLOs. This novel M.tb infection model can be cultured long-term and split several times while maintaining a similar number of M.tb H37Rv inside the hLOs. Anti-TB drugs reduced the intracellular survival of M.tb in hLOs. Notably, M.tb growth in hLOs was effectively suppressed at each passage by rifampicin and bedaquiline. Furthermore, a reduction in inflammatory cytokine production and intracellular survival of M.tb were observed upon knockdown of MFN2 and HERPUD1 (host-directed therapeutic targets for TB) in our M.tb H37Rv-infected hLO model. Thus, the incorporation of hMφs and M.tb into hLOs provides a powerful strategy for generating an M.tb infection model. This model can effectively reflect host-pathogen interactions and be utilized to test the efficacy of anti-TB drugs and host-directed therapies., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Kim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
27. Increased Incidence of Severe Adverse Events in Non-Small Cell Lung Cancer Patients with Previous Tuberculosis Episode Treated with PD-1 Inhibitors.
- Author
-
Zhang H, Yuan JF, Xu YY, Yang MJ, Lyu JL, Yang XJ, Sheng SY, Qian Z, Wang QH, Pang Y, and Hu Y
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Incidence, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary epidemiology, Aged, 80 and over, Retrospective Studies, Lung Neoplasms drug therapy, Immune Checkpoint Inhibitors adverse effects, Immune Checkpoint Inhibitors therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy
- Abstract
Lung cancer is the top cause of cancer deaths globally. Advances in immune checkpoint inhibitors (ICIs) have transformed cancer treatment, but their use in lung cancer has led to more side effects. This study examined if past pulmonary tuberculosis (TB) affects ICIs' effectiveness and safety in lung cancer treatment. We reviewed lung cancer patients treated with ICIs at Beijing Chest Hospital from January 2019 to August 2022. We compared outcomes and side effects between patients with and without prior TB. Of 116 patients (40 with TB history, 76 without), prior TB didn't reduce treatment effectiveness but did increase severe side effects. Notably, older patients (≥ 65 years) faced a higher risk of severe side effects. Detailed cases of two patients with severe side effects underscored TB as a risk factor in lung cancer patients receiving ICIs, stressing the need for careful monitoring and personalized care., (Copyright © 2024 The Editorial Board of Biomedical and Environmental Sciences. Published by China CDC. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. Hemophagocytic lymphohistiocytosis secondary to rifampin treatment: A case report.
- Author
-
Wang C, Qiu J, Huang X, Xu J, and Pan L
- Subjects
- Humans, Female, Middle Aged, Tuberculosis, Pulmonary drug therapy, Antitubercular Agents adverse effects, Antitubercular Agents therapeutic use, Lymphohistiocytosis, Hemophagocytic chemically induced, Lymphohistiocytosis, Hemophagocytic drug therapy, Lymphohistiocytosis, Hemophagocytic diagnosis, Rifampin adverse effects, Rifampin therapeutic use
- Abstract
Rationale: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening systemic inflammatory syndrome characterized by an overactive immune response. This hyperactivation can arise from genetic mutations, infections, malignancies, or autoimmune disorders. Medication-induced HLH is extremely rare and requires special attention., Patient Concerns: A 53-year-old female diagnosed with pulmonary and urinary tract tuberculosis. She underwent quadruple therapy, including isoniazid, rifampin, ethambutol, and pyrazinamide. Subsequently, she developed fever, hepatosplenomegaly, pancytopenia, hypertriglyceridemia, hypofibrinogenemia, hyperferritinemia, increased soluble CD25 levels, decreased natural killer cell activity, and hemophagocytosis, notably without eosinophilia. Her clinical symptoms were exacerbated by rifampin intake., Diagnoses: Pulmonary and left kidney tuberculosis, multiple organ failure, and rifampin-induced HLH., Interventions: Anti-tuberculosis regimen (isoniazid, pyrazinamide, ethambutol, and levofloxacin, excluding rifampin) combined with glucocorticoid therapy., Outcomes: Satisfactory recovery with improved clinical symptoms, laboratory tests, and chest imaging studies., Lessons: Early correct diagnosis and appropriate management of HLH are essential to save the lives of affected patients. The potential severe side effects of rifampin should not be ignored., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
29. Rifabutin loaded inhalable β-glucan microparticle based drug delivery system for pulmonary TB.
- Author
-
Ahmad F, Ahmad S, Upadhyay TK, Singh S, Khubaib M, Singh J, Saeed M, Ahmad I, Al-Keridis LA, and Sharma R
- Subjects
- Humans, Administration, Inhalation, Tuberculosis, Pulmonary drug therapy, Particle Size, Macrophages metabolism, Macrophages drug effects, Drug Carriers chemistry, Antitubercular Agents administration & dosage, Antitubercular Agents pharmacokinetics, Antitubercular Agents chemistry, Rifabutin administration & dosage, Rifabutin pharmacokinetics, Rifabutin chemistry, beta-Glucans chemistry, Drug Delivery Systems
- Abstract
Inhalable microparticle-based anti TB drug delivery systems are being investigated extensively for Tuberculosis [TB] treatment as they offer efficient and deep lung deposition with several advantages over conventional routes. It can reduce the drug dose, treatment duration and toxic effects and optimize the drug bioavailability. Yeast derived β-glucan is a β-[1-3/1-6] linked biocompatible polymer and used as carrier for various biomolecules. Due to presence of glucan chains, particulate glucans act as PAMP and thereby gets internalized via receptor mediated phagocytosis by the macrophages. In this study, β-glucan microparticles were prepared by adding l-leucine as excipient, and exhibited 70% drug [Rifabutin] loading efficiency. Further, the sizing and SEM data of particles revealed a size of 2-4 µm with spherical dimensions. The FTIR and HPLC data confirmed the β-glucan composition and drug encapsulations efficiency of the particles. The mass median aerodynamic diameter [MMAD] and geometric standard deviation [GSD] data indicated that these particles are inhalable in nature and have better thermal stability as per DSC thermogram. These particles were found to be non-toxic upto a concentration of 80 µg/ml and were found to be readily phagocytosed by human macrophage cells in-vitro as well as in-vivo by lung alveolar macrophage. This study provides a framework for future design of inhalable β-glucan particle based host-directed drug delivery system against pulmonary TB., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
30. Effectiveness of food supplement on treatment outcomes and quality of life in pulmonary tuberculosis: Phased implementation approach.
- Author
-
Mahapatra A, Thiruvengadam K, Nair D, Padmapriyadarsini C, Thomas B, Pati S, Bulliyya G, Das D, Chowdhury J, Bang A, and Swaminathan S
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Treatment Outcome, India, Young Adult, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary psychology, Quality of Life, Dietary Supplements, Antitubercular Agents therapeutic use
- Abstract
Background: By encouraging treatment adherence and lowering mortality, dietary supplements can serve as adjuvant therapy for the success of medical interventions. We determined the effect of locally accessible food supplements on treatment outcomes, and health-related quality of life in patients with pulmonary tuberculosis initiating anti-tuberculosis treatment (ATT) in Odisha, India., Method: Between September 2017 and December 2018, implementation research in patients with newly diagnosed sputum smear-positive pulmonary tuberculosis initiating ATT in five districts of the tribal belt of Odisha, offered food supplements along with ATT in a phased manner. Clinical symptoms, anthropometry, sputum for M. tuberculosis (M. tb), health-related quality of life and return to normal function were assessed periodically, and favourable treatment outcome (cure or treatment completed) was measured at the end of treatment. The effect of the food supplement on unfavorable outcomes (treatment failure, death, or lost-to-follow-up) was modelled using mixed-effects Poisson regression to determine the risk factors., Results: Among the 761 participants enrolled, 614 participants received the food supplement and 147 did not receive the food supplement. Among the 614 participants in the supplement group, 537 (87%) had a favorable outcome and among the 147 participants in the no-supplement group, 113 (77%) had a favorable outcome (p = 0.0017). Higher age (>55 years) [aRR = 2.1(95% CI: 1.1-3.8)], male gender [aRR = 1.7(95% CI: 1.2-2.9)], and smear grading ≥2+ [aRR = 1.5 (95% CI: 1.1-2.2)] were associated with unfavorable treatment outcomes. Nutritional status, quality of life and lung health showed significant improvement from baseline in the supplement group., Conclusion: Improvement in the nutritional status of the patient can be considered a predictor of treatment success rates. Early food supplementation has a positive impact on the nutritional status., Competing Interests: JC & AB are employees of TATA TRUSTS. Rest of the authors have declared that no competing interests exist., (Copyright: © 2024 Mahapatra et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
31. [Clinical analysis of adverse reactions in patients with multidrug-resistant and rifampicin-resistant pulmonary tuberculosis treated with delamanid-containing regimen].
- Author
-
Gao MQ, Gao JT, Ma XG, Shu W, Du J, Liang RX, Wu GH, Pei Y, Yan XF, Cai QS, Lyu KY, Cai C, Wu YQ, Li XJ, Liu QQ, Jin L, Wu QH, Xiong Y, Li MW, Zhou YQ, Kuang HB, Wang XF, Ren F, Chen XH, Geng SJ, Zhou Y, Sha W, Yang GL, Wang H, Zhan Y, Liu YH, and Li L
- Subjects
- Humans, Male, Female, Adult, Prospective Studies, Middle Aged, Aged, China, Young Adult, Drug-Related Side Effects and Adverse Reactions etiology, Tuberculosis, Multidrug-Resistant drug therapy, Rifampin adverse effects, Oxazoles adverse effects, Oxazoles therapeutic use, Oxazoles administration & dosage, Antitubercular Agents adverse effects, Tuberculosis, Pulmonary drug therapy, Nitroimidazoles adverse effects, Nitroimidazoles therapeutic use, Nitroimidazoles administration & dosage
- Abstract
Objective: To explore the characteristics of adverse drug reactions during the 24-week therapy with delamanid-containing regimen for patients with multidrug-resistant and rifampicin-resistant pulmonary tuberculosis (MDR/RR-PTB). Methods: The prospective multicenter study was conducted from June 2020 to June 2023. A total of 608 eligible patients with MDR/RR-PTB were enrolled in 26 tuberculosis medical institutions in China including 364 males and 79 females, aged 39.6(19.0-68.0) years. Patients were treated with chemotherapy regimens containing delamanid. Patients were closely supervised during treatment of medication, and all adverse reactions occurring during treatment were monitored and recorded. The clinical characteristics of adverse reactions were evaluated by descriptive analysis. Chi-square test and multivariate logistic regression were used to analyze the related factors of QTcF interval prolongation (QT corrected with Fridericia's formula). Results: Of the 608 patients enrolled in this study, 325 patients (53.5%) reported 710 adverse events within 24 weeks of treatment. The top 6 most common complications were hematological abnormalities (143 patients, 23.5%), QT prolongation (114 patients, 18.8%), liver toxicity (85 patients, 14.0%), gastrointestinal reaction (41 patients, 6.7%), peripheral neuropathy (25 patients, 4.1%) and mental disorders (21 patients, 3.5%). The prolongation of QT interval mostly occurred in the 12th week after the first dose of medication. Serious adverse reactions occurred in 21 patients (3.5%). There were 7 patients (1.2%) with mental disorders, including 2 patients (0.3%) with severe mental disorders. Conclusions: The safety of dalamanid-based regimen in the staged treatment of MDR/RR-PTB patients was generally good, and the incidence of adverse reactions was similar to that reported in foreign studies. This study found that the incidence of QT interval prolongation in Chinese patients was higher than that reported overseas, suggesting that the monitoring of electrocardiogram should be strengthened when using drugs containing delamanid that may cause QT interval prolongation.
- Published
- 2024
- Full Text
- View/download PDF
32. The mechanism of Gejie Zhilao Pill in treating tuberculosis based on network pharmacology and molecular docking verification.
- Author
-
Gao Y, Shang B, He Y, Deng W, Wang L, and Sui S
- Subjects
- Humans, Protein Interaction Maps, Medicine, Chinese Traditional, Antitubercular Agents pharmacology, Antitubercular Agents therapeutic use, Antitubercular Agents chemistry, Mycobacterium tuberculosis drug effects, Tuberculosis drug therapy, Tuberculosis microbiology, Signal Transduction drug effects, Animals, Gene Ontology, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary microbiology, Molecular Docking Simulation, Drugs, Chinese Herbal pharmacology, Drugs, Chinese Herbal chemistry, Network Pharmacology
- Abstract
Introduction: Gejie Zhilao Pill (GJZLP), a traditional Chinese medicine formula is known for its unique therapeutic effects in treating pulmonary tuberculosis. The aim of this study is to further investigate its underlying mechanisms by utilizing network pharmacology and molecular docking techniques., Methods: Using TCMSP database the components, potential targets of GJZLP were identified. Animal-derived components were supplemented through the TCMID and BATMAN-TCM databases. Tuberculosis-related targets were collected from the TTD, OMIM, and GeneCards databases. The intersection target was imported into the String database to build the PPI network. The Metascape platform was employed to carry out Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Heatmaps were generated through an online platform (https://www.bioinformatics.com.cn). Molecular docking was conducted between the core targets and core compounds to explore their binding strengths and patterns at the molecular level., Results: 61 active ingredients and 118 therapeutic targets were identified. Quercetin, Luteolin, epigallocatechin gallate, and beta-sitosterol showed relatively high degrees in the network. IL6, TNF, JUN, TP53, IL1B, STAT3, AKT1, RELA, IFNG, and MAPK3 are important core targets. GO and KEGG revealed that the effects of GJZLP on tuberculosis mainly involve reactions to bacterial molecules, lipopolysaccharides, and cytokine stimulation. Key signaling pathways include TNF, IL-17, Toll-like receptor and C-type lectin receptor signaling. Molecular docking analysis demonstrated a robust binding affinity between the core compounds and the core proteins. Stigmasterol exhibited the lowest binding energy with AKT1, indicating the most stable binding interaction., Discussion: This study has delved into the efficacious components and molecular mechanisms of GJZLP in treating tuberculosis, thereby highlighting its potential as a promising therapeutic candidate for the treatment of tuberculosis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Gao, Shang, He, Deng, Wang and Sui.)
- Published
- 2024
- Full Text
- View/download PDF
33. Laryngeal tuberculosis, the great deceiver: A series of 10 cases.
- Author
-
Teixeira Marques F, Estêvão R, Mota CP, and Lousan N
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Antitubercular Agents therapeutic use, Aged, Vocal Cords pathology, Smoking adverse effects, Retrospective Studies, Diagnosis, Differential, Laryngopharyngeal Reflux diagnosis, Tuberculosis, Laryngeal diagnosis, Tuberculosis, Laryngeal drug therapy, Laryngoscopy, Hoarseness etiology, Tuberculosis, Pulmonary diagnosis, Tuberculosis, Pulmonary drug therapy
- Abstract
Background: Laryngeal involvement is rare in tuberculosis, representing around 1% of all cases of this infection worldwide. Given the larynx' location in the airway, this form of tuberculosis is of particular importance because it is highly contagious. With our hospital being in a high tuberculosis burden area, we propose to characterize the clinical presentation, evolution, and laryngoscopy findings of a series of laryngeal tuberculosis cases in order to reduce misdiagnosis., Methods: Epidemiological and clinical data from 10 patients diagnosed with laryngeal tuberculosis in the Otorhinolaryngology department of (Blinded for manuscript) between January 2011 and December 2021 were retrieved and analyzed., Results: There were eight males and two females. Seven patients had a history of smoking and alcohol abuse and four had silicosis. Hoarseness was the most reported symptom (n = 9). The most frequent site of involvement were the true vocal cords (n = 6). All patients but one had concomitant active pulmonary tuberculosis. Patients had full resolution of laryngeal symptoms between 4 and 16 weeks after initiating antituberculosis treatment., Conclusion: Laryngeal tuberculosis is indeed a great deceiver. On one hand it can look like a simple polypoid lesion or simulate laryngopharyngeal reflux; but on the other hand its risk factors, symptoms and appearance simulate laryngeal carcinoma like no other. Since most patients present with concomitant pulmonary tuberculosis, all suspect laryngeal lesions should perform a chest radiograph prior to rigid laryngoscopy. Antituberculosis treatment is effective in both alleviating symptoms and reducing the risk of transmission., Competing Interests: Declaration of competing interest None of the authors have any conflict of interest, financial or non-financial., (Copyright © 2024 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
34. Factors affecting tuberculosis treatment outcome among newly diagnosed tuberculosis patients - A longitudinal study.
- Author
-
Umayorubhagom A and Baliga SS
- Subjects
- Humans, Male, Female, Adult, Longitudinal Studies, Treatment Outcome, Middle Aged, Young Adult, India epidemiology, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary diagnosis, Tuberculosis, Pulmonary epidemiology, Adolescent, Tuberculosis diagnosis, Tuberculosis drug therapy, Tuberculosis epidemiology, Cough etiology, Age Factors, Logistic Models, Social Support, Antitubercular Agents therapeutic use
- Abstract
Background: Tuberculosis disease epidemiology is closely related to social and economic conditions which make its prevention, control and cure challenging. Early diagnosis and adequate treatment will help to prevent various tuberculosis related morbidities. Factors such as adverse effects of drugs, transportation cost, family support, distance to the treatment center, personal habits, co morbid conditions, and patients' multiple obligations concerning to their employment, family and society have an impact on the treatment outcomes., Objective: To know the factors affecting tuberculosis treatment outcome among newly diagnosed tuberculosis patients., Materials and Methods: A total of 261 Tuberculosis patients registered in NTEP under District tuberculosis centre were enrolled using universal sampling method. First follow up was done at the end of intensive phase i.e. End of 2 months. Second follow up was done after completion of treatment i.e., End of 6th month., Results: Majority 59% participants were diagnosed as smear negative at 2nd month follow up and 45.21% and 28.73% participants were diagnosed as cured and treatment completed respectively at 6th month follow up. 73.95% participants had successful outcome. Multivariate logistic regression analysis showed that treatment outcomes of tuberculosis were affected by type of house (pucca house), presence of cough, past history of tuberculosis, family support, supervision by family and support of supervisor., Conclusion: Overall treatment success rate was 73.95%. The contributing factors for successful outcome of tuberculosis were age, past history of TB, type of house, presence of cough and fever, weight gain, family support, supervision by family and support of supervisor., Competing Interests: Conflicts of interest The authors have none to declare., (Copyright © 2023 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
35. Bedaquiline: An Insight Into its Clinical Use in Multidrug-Resistant Pulmonary Tuberculosis.
- Author
-
Ahmad A, Akhtar J, Ahmad M, Khan MI, Wasim R, Islam A, and Singh A
- Subjects
- Humans, Microbial Sensitivity Tests, Animals, Diarylquinolines therapeutic use, Diarylquinolines pharmacokinetics, Antitubercular Agents therapeutic use, Antitubercular Agents pharmacokinetics, Antitubercular Agents pharmacology, Antitubercular Agents administration & dosage, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary microbiology, Mycobacterium tuberculosis drug effects
- Abstract
Every year, the World Health Organization reports 500,000 new cases of drug-resistant tuberculosis (TB), which poses a serious global danger. The increased number of XDR-TB and MDR-TB cases reported worldwide necessitates the use of new therapeutic approaches. The main issues with the antitubercular medications now in use for the treatment of multidrug-resistant tuberculosis are their poor side effect profile, reduced efficacy, and antimicrobial resistance. One possible remedy for these problems is bedaquiline. The need for better treatment strategies is highlighted by the strong minimum inhibitory concentrations that bedaquiline (BDQ), a novel anti-TB medicine, exhibits against both drug-resistant and drug-susceptible TB. Bedaquiline may be able to help with these problems. Bedaquiline is a medication that is first in its class and has a distinct and particular mode of action. Bedaquiline is an ATP synthase inhibitor that is specifically directed against Mycobacterium tuberculosis and some nontuberculous mycobacteria. It is metabolized by CYP3A4. Bedaquiline preclinical investigations revealed intralesional drug biodistribution. The precise intralesional and multi-compartment pharmacokinetics of bedaquiline were obtained using PET bioimaging and high-resolution autoradiography investigations. Reduced CFU counts were observed in another investigation after a 12-week course of therapy. Meta-analyses and systematic reviews of phase II trials on bedaquiline's efficacy in treating drug-resistant tuberculosis in patients reported higher rates of cure, better culture conversion, and lower death rates when taken in conjunction with a background regimen. Here is a thorough medication profile for bedaquiline to aid medical professionals in treating individuals with tuberculosis., Competing Interests: The authors declare that they have no conflict of interest., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
36. Pharmacokinetic and Pharmacodynamic Modeling Analysis of Delpazolid (LCB01-0371) in Adult Patients with Pulmonary Tuberculosis.
- Author
-
Lee SM, Choi SC, Mun KR, Seo JY, Cho YL, Shim TS, and Lim HS
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Aged, Antitubercular Agents pharmacokinetics, Antitubercular Agents therapeutic use, Antitubercular Agents administration & dosage, Young Adult, Dose-Response Relationship, Drug, Administration, Oral, Oxazolidinones pharmacokinetics, Oxazolidinones administration & dosage, Oxazolidinones therapeutic use, Tuberculosis, Pulmonary drug therapy, Models, Biological
- Abstract
Delpazolid (LCB01-0371) is a novel oxazolidinone derivative with a good safety profile for treating gram-positive pathogenic infections such as Mycobacterium abscessus, a highly pathogenic drug-resistant Mycobacterium. In this study, we evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) of delpazolid after 14 days of multiple oral administration, using data from adult patients with pulmonary tuberculosis. 800 mg once a day, 400 mg twice a day, 800 mg twice a day, and 1200 mg once a day delpazolid for 14 days were tested in 63 patients with pulmonary tuberculosis. For PK blood collection, inpatient and outpatient scheduling were separately implemented. Plasma concentrations of delpazolid were measured at visits 2, 4, 6, and 8 in outpatients, and four sparse blood samples were measured in inpatients. PD models were sequentially fitted using individual PK parameter estimates obtained from PK compartmental models. For PK modeling, 180 plasma concentrations of delpazolid from 56 patients were included. A two-compartment mixed first- and zero-order absorption model best described the time course of plasma concentration. For the PD model, 448 bacterial titer data from 60 patients were used. The time course of bacterial titers (log
10 CFU/mL) was described by a model that consists of the growth and killing rate of bacteria with the sigmoid Emax model. The PK-PD simulation suggested that the bacterial titers are the lowest on the 800 mg bid regimen among the four, consistent with observed data, as all regimens substantially decrease. In the dose-response relationship, the effectiveness of delpazolid was suggested., (© 2024, The American College of Clinical Pharmacology.)- Published
- 2024
- Full Text
- View/download PDF
37. Efficacy and Safety of Bufei Jiedu Granules in Treating Multidrug-Resistant Pulmonary Tuberculosis: A Multi-center, Double-Blinded and Randomized Controlled Trial.
- Author
-
Zhang SY, Qiu L, Zhang SX, Xiao HP, Chu NH, Zhang X, Zhang HQ, Zheng PY, Zhang HY, and Lu ZH
- Subjects
- Humans, Double-Blind Method, Female, Male, Adult, Middle Aged, Quality of Life, Treatment Outcome, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Multidrug-Resistant drug therapy, Drugs, Chinese Herbal therapeutic use, Drugs, Chinese Herbal adverse effects
- Abstract
Objective: To assess the efficacy and safety of Bufei Jiedu (BFJD) ranules as adjuvant therapy for patients with multidrug-resistant pulmonary tuberculosis (MDR-PTB)., Methods: A large-scale, multi-center, double-blinded, and randomized controlled trial was conducted in 18 sentinel hospitals in China from December 2012 to December 2016. A total of 312 MDR-PTB patients were randomly assigned to BFJD Granules or placebo groups (1:1) using a stratified randomization method, which both received the long-course chemotherapy regimen for 18 months (6 Am-Lfx-P-Z-Pto, 12 Lfx-P-Z-Pto). Meanwhile, patients in both groups also received BFJD Granules or placebo twice a day for a total of 18 months, respectively. The primary outcome was cure rate. The secondary outcomes included time to sputum-culture conversion, changes in lung cavities and quality of life (QoL) of patients. Adverse reactions were monitored during and after the trial., Results: A total of 216 cases completed the trial, 111 in the BFJD Granules group and 105 in the placebo group. BFJD Granules, as an adjuvant treatment, increased the cure rate by 13.6% at the end of treatment, compared with the placebo (58.4% vs. 44.8%, P=0.02), and accelerated the median time to sputum-culture conversion (5 months vs. 11 months). The cavity closure rate of the BFJD Granules group (50.6%, 43/85) was higher than that of the placebo group (32.1%, 26/81; P=0.02) in patients who completed the treatment. At the end of the intensive treatment, according to the 36-item Short Form, the BFJD Granules significantly improved physical functioning, general health, and vitality of patients relative to the placebo group (all P<0.01). Overall, the death rates in the two groups were not significantly different; 5.1% (8/156) in the BFJD Granules group and 2.6% (4/156) in the placebo group., Conclusions: Supplementing BFJD Granules with the long-course chemotherapy regimen significantly increased the cure rate and cavity closure rates, and rapidly improved QoL of patients with MDR-PTB (Registration No. ChiCTR-TRC-12002850)., (© 2024. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
38. A blood-based 3-gene signature score for therapeutic monitoring in patients with pulmonary tuberculosis.
- Author
-
Zhang P, Zheng J, Han T, Ma J, Gnanashanmugam D, Li M, Tang YW, and Deng G
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Drug Monitoring methods, Treatment Outcome, Reproducibility of Results, Aged, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Multidrug-Resistant diagnosis, Tuberculosis, Multidrug-Resistant blood, Tuberculosis, Multidrug-Resistant microbiology, Time Factors, Biomarkers blood, Gene Expression Profiling methods, Young Adult, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary diagnosis, Tuberculosis, Pulmonary blood, Tuberculosis, Pulmonary microbiology, Antitubercular Agents therapeutic use, Mycobacterium tuberculosis genetics, Sputum microbiology, Predictive Value of Tests
- Abstract
Objective: To assess the validity of Xpert Tuberculosis Fingerstick score for monitoring treatment response and analyze factors influencing its performance., Methods: 122 adults with pulmonary tuberculosis were recruited and stratified into three cohorts: Diabetic-drug-susceptible-TB (DM-TB), Non-diabetic-drug-susceptible-TB (NDM-TB) and Non-diabetic Multidrug-resistant TB (MDR-TB). Fingerstick blood specimens were tested at treatment initiation (M0) and the end of the first (M1), second (M2), and sixth month (M6) to generate a TB-score., Results: The TB-score in all participants yielded an AUC of 0.707 (95% CI: 0.579-0.834) at M2 when its performance was evaluated against sputum culture conversion. In all non-diabetes patients, the AUC reached 0.88 (95% CI: 0.756-1.000) with an optimal cut-off value of 1.95 at which sensitivity was 90.0% (95% CI: 59.6-98.2%) and specificity was 81.3% (95% CI: 70.0-88.9%). The mean TB score was higher in patients with low bacterial loads (n = 31) than those with high bacterial loads (n = 91) at M0, M1, M2, and M6, and was higher in non-cavitary patients (n = 71) than those with cavitary lesions (n = 51) at M0, M1, and M2., Conclusion: Xpert TB-score shows promising predictive value for culture conversion in non-diabetic TB patients. Sputum bacterial load and lung cavitation status have an influence on the value of TB score., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
39. Effect of complicated, untreated and uncontrolled diabetes and pre-diabetes on treatment outcome among patients with pulmonary tuberculosis.
- Author
-
Kim KH, Kim HW, Kim YH, Park Y, Jung SS, Kim JW, Oh JY, Lee H, Kim SK, Kim SH, Lyu J, Ko Y, Kwon SJ, Jeong YJ, Kim DJ, Koo HK, Jegal Y, Kyung SY, Lee SS, Park JS, Kim JS, and Min J
- Subjects
- Humans, Male, Female, Middle Aged, Treatment Outcome, Prospective Studies, Adult, Republic of Korea epidemiology, Risk Factors, Registries, Diabetes Mellitus epidemiology, Aged, Diabetes Complications, Tuberculosis, Pulmonary mortality, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary complications, Tuberculosis, Pulmonary epidemiology, Antitubercular Agents therapeutic use, Prediabetic State epidemiology, Prediabetic State complications
- Abstract
Background and Objective: Patients with tuberculosis and diabetes have a higher risk of unfavourable anti-tuberculosis treatment outcomes. In the present study, we aimed to evaluate the effects of various diabetes statuses on the outcomes of patients with pulmonary tuberculosis., Methods: Among the patients with pulmonary tuberculosis enrolled in the Korea Tuberculosis Cohort (KTBC) registry and the multicentre prospective cohort study of pulmonary tuberculosis (COSMOTB), those with diabetes and complicated diabetes were identified. The primary and secondary outcomes were unfavourable outcomes and mortality, respectively. The effect of diabetes and complicated diabetes on the outcomes was assessed using multivariable logistic regression analysis. Using COSMOTB, subgroup analyses were performed to assess the association between various diabetes statuses and outcomes., Results: In the KTBC, diabetes (adjusted odds ratio [aOR] = 1.93, 95% CI = 1.64-2.26) and complicated diabetes (aOR = 1.96, 95% CI = 1.67-2.30) were significantly associated with unfavourable outcomes, consistent with the COSMOTB data analysis. Based on subgroup analysis, untreated diabetes at baseline was an independent risk factor for unfavourable outcomes (aOR = 2.72, 95% CI = 1.26-5.61). Prediabetes and uncontrolled diabetes increased unfavourable outcomes and mortality without statistical significance., Conclusion: Untreated and complicated diabetes at the time of tuberculosis diagnosis increases the risk of unfavourable outcomes and mortality., (© 2024 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.)
- Published
- 2024
- Full Text
- View/download PDF
40. Baseline and end-of-treatment host serum biomarkers predict relapse in adults with pulmonary tuberculosis.
- Author
-
Mutavhatsindi H, Manyelo CM, Snyders CI, Van Rensburg I, Kidd M, Stanley K, Tromp G, Dietze R, Thiel B, van Helden PD, Belisle JT, Johnson JL, Boom WH, Walzl G, and Chegou NN
- Subjects
- Humans, Male, Female, Adult, Uganda, South Africa, Middle Aged, Brazil, Young Adult, Chemokine CXCL10 blood, Interleukins blood, Cytokines blood, Complement C3 analysis, Biomarkers blood, Tuberculosis, Pulmonary blood, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary diagnosis, Recurrence, Antitubercular Agents therapeutic use
- Abstract
Background: There is a need for new tools for monitoring of the response to TB treatment. Such tools may allow for tailored treatment regimens, and stratify patients initiating TB treatment into different risk groups. We evaluated combinations between previously published host biomarkers and new candidates, as tools for monitoring TB treatment response, and prediction of relapse., Methods: Serum samples were collected at multiple time points, from patients initiating TB treatment at research sites situated in South Africa (ActionTB study), Brazil and Uganda (TBRU study). Using a multiplex immunoassay platform, we evaluated the concentrations of selected host inflammatory biomarkers in sera obtained from clinically cured patients with and without subsequent relapse within 2 years of TB treatment completion., Results: A total of 130 TB patients, 30 (23%) of whom had confirmed relapse were included in the study. The median time to relapse was 9.7 months in the ActionTB study (n = 12 patients who relapsed), and 5 months (n = 18 patients who relapsed) in the TBRU study. Serum concentrations of several host biomarkers changed during TB treatment with IL-6, IP-10, IL-22 and complement C3 showing potential individually, in predicting relapse. A six-marker signature comprising of TTP, BMI, sICAM-1, IL-22, IL-1β and complement C3, predicted relapse, prior to the onset of TB treatment with 89% sensitivity and 94% specificity. Furthermore, a 3-marker signature (Apo-CIII, IP-10 and sIL-6R) predicted relapse in samples collected at the end of TB treatment with sensitivity of 71% and specificity of 74%. A previously identified baseline relapse prediction signature (TTP, BMI, TNF-β, sIL-6R, IL-12p40 and IP-10) also showed potential in the current study., Conclusion: Serum host inflammatory biomarkers may be useful in predicting relapse in TB patients prior to the initiation of treatment. Our findings have implications for tailored patient management and require prospective evaluation in larger studies., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
41. Inhibition of leukotriene-B4 signalling-mediated host response to tuberculosis is a potential mode of adjunctive host-directed therapy.
- Author
-
Banerjee U, Borbora SM, Guha M, Yadav V, Sanjay V, Singh A, Balaji KN, and Chandra N
- Subjects
- Humans, Antitubercular Agents therapeutic use, Antitubercular Agents pharmacology, Male, Female, Adult, Middle Aged, NADPH Oxidases metabolism, Host-Pathogen Interactions, Signal Transduction, Leukotriene B4 metabolism, Tuberculosis, Pulmonary immunology, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary metabolism, Mycobacterium tuberculosis immunology
- Abstract
Treatment of tuberculosis (TB) is faced with several challenges including the long treatment duration, drug toxicity and tissue pathology. Host-directed therapy provides promising avenues to find compounds for adjunctively assisting antimycobacterials in the TB treatment regimen, by promoting pathogen eradication or limiting tissue destruction. Eicosanoids are a class of lipid molecules that are potent mediators of inflammation and have been implicated in aspects of the host response against TB. Here, we have explored the blood transcriptome of pulmonary TB patients to understand the activity of leukotriene B4, a pro-inflammatory eicosanoid. Our study shows a significant upregulation in the leukotriene B4 signalling pathway in active TB patients, which is reversed with TB treatment. We have further utilized our in-house network analysis algorithm, ResponseNet, to identify potential downstream signal effectors of leukotriene B4 in TB patients including STAT1/2 and NADPH oxidase at a systemic as well as local level, followed by experimental validation of the same. Finally, we show the potential of inhibiting leukotriene B4 signalling as a mode of adjunctive host-directed therapy against TB. This study provides a new mode of TB treatment along with mechanistic insights which can be further explored in pre-clinical trials., (© 2024 John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
42. Death after cure: Mortality among pulmonary tuberculosis survivors in rural Uganda.
- Author
-
Baluku JB, Namanda B, Namiiro S, Rwabwera DK, Mwesigwa G, Namaara C, Twinomugisha B, Nyirazihawe I, Nuwagira E, Kansiime G, Kizito E, Nabukenya-Mudiope MG, Sekadde MP, Bongomin F, Senfuka J, Olum R, Byaruhanga A, Munabi I, and Kiguli S
- Subjects
- Humans, Uganda epidemiology, Female, Male, Retrospective Studies, Adult, Middle Aged, Young Adult, Incidence, Hospitalization, Adolescent, Proportional Hazards Models, Antitubercular Agents therapeutic use, Risk Factors, Tuberculosis, Pulmonary mortality, Tuberculosis, Pulmonary drug therapy, Rural Population, Survivors
- Abstract
Objectives: To determine the incidence of mortality and its predictors among pulmonary tuberculosis (PTB) survivors treated at a rural Ugandan tertiary hospital., Methods: We conducted a retrospective chart review of data between 2013 and 2023. We included all people that met the World Health Organisation's definition of tuberculosis cure and traced them or their next of kin to determine vital status (alive/deceased). We estimated the cumulative incidence of mortality per 1000 population, crude all-cause mortality rate per 1000 person-years, and median years of potential life lost for deceased individuals. Using Cox proportional hazard models, we investigated predictors of mortality., Results: Of 334 PTB survivors enrolled, 38 (11.4%) had died. The cumulative incidence of all-cause mortality was 113.7 per 1000 population, and the crude all-cause mortality rate was 28.5 per 1000 person-years. The median years of potential life lost for deceased individuals was 23.8 years (IQR: 9.6-32.8). Hospitalization (adjusted hazard ratio (aHR): 4.3, 95% CI: 1.1-16.6) and unemployment (aHR: 7.04, 95% CI: 1.5-31.6) at TB treatment initiation predicted mortality., Conclusion: PTB survivors experience post high mortality rates after TB cure. Survivors who were hospitalized and unemployed at treatment initiation were more likely to die after cure. Social protection measures and long-term follow-up of previously hospitalized patients could improve the long-term survival of TB survivors., Competing Interests: Declaration of competing interest The authors declare no conflict of interests., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
43. T cells exhaustion, inflammatory and cellular activity markers in PBMCs predict treatment outcome in pulmonary tuberculosis patients.
- Author
-
Nii Otinkorang Ankrah J, Gyilbagr F, Vicar EK, Antwi Boasiako Frimpong E, Alhassan RB, Sibdow Baako I, Boakye AN, Akwetey SA, Karikari AB, Sorvor FKB, and Walana W
- Subjects
- Humans, Male, Female, Adult, Treatment Outcome, Middle Aged, B7-H1 Antigen metabolism, GATA3 Transcription Factor metabolism, Lectins, C-Type metabolism, T-Lymphocytes metabolism, T-Lymphocytes immunology, Antigens, Differentiation, T-Lymphocyte metabolism, Mycobacterium tuberculosis immunology, Interleukin-2 metabolism, Ki-67 Antigen metabolism, Tumor Necrosis Factor-alpha metabolism, Inflammation metabolism, Interferon-gamma metabolism, Tuberculosis, Pulmonary immunology, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary metabolism, Tuberculosis, Pulmonary blood, Leukocytes, Mononuclear metabolism, Antigens, CD metabolism, Biomarkers metabolism, Lymphocyte Activation Gene 3 Protein, CTLA-4 Antigen metabolism
- Abstract
Background: Pulmonary tuberculosis (PTB) is a well-known disease caused by Mycobacterium tuberculosis. Its pathogenesis is premised on evasion of the immune system and dampened immune cells activity., Methods: Here, the transcription pattern of immune cells exhaustion, inflammatory, and cellular activity markers were examined in peripheral blood mononuclear cells (PBMCs) from PTB patients at various stages of treatment. PBMCs were isolated, and RNA extracted. cDNA synthesis was performed, then amplification of genes of interest., Results: The T cell exhaustion markers (PD-L1, CTLA4, CD244 and LAG3) showed varied levels of expressions when comparing 0 T and 1 T to the other treatment phases, suggesting their potential roles as markers for monitoring TB treatment. IL-2, IFN-g and TNF-a expression at the gene level returned to normal at completion of treatment, while granzyme B levels remained undetectable at the cured stage. At the cured stage, the cellular activity monitors Ki67, CD69, GATA-3, CD8 and CD4 expressions were comparable to the healthy controls. Correlation analysis revealed a significantly strong negative relationship with CD244 expression, particularly between 1 T and 2 T (r = -0.94; p = 0.018), and 3 T (r = -0.95; p = 0.013). Comparing 0 T and 3 T, a genitive correlation existed in PD-L1 (r = -0.74) but statistically not significant, as seen in CTLA4 and LAG-3 expressions., Conclusion: Collectively, the findings of the study suggest that T-cells exhaustion marker particularly CD244, inflammatory markers IL-2, IFN-g and TNF-a, and cellular activity indicators such as Ki67, CD69, GATA-3, CD8 and CD4 are promising markers in monitoring the progress of PTB patients during treatment., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
44. Fatal co-infection by multiple pathogens in an indigenous woman with autoimmune hemolytic anemia and tuberculosis: a case report.
- Author
-
Tabares B, Sarmiento-Suárez AD, Gil Ó, Hernández-Pabón JC, and Firacative C
- Subjects
- Humans, Female, Adult, Fatal Outcome, Colombia, Klebsiella pneumoniae isolation & purification, Staphylococcus aureus isolation & purification, Candida glabrata isolation & purification, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary complications, Tuberculosis, Pulmonary microbiology, Staphylococcal Infections microbiology, Indigenous Peoples, Candidiasis drug therapy, Candidiasis microbiology, Coinfection microbiology, Anemia, Hemolytic, Autoimmune complications
- Abstract
Background: Tuberculosis (TB), one of the leading causes of death worldwide, has a higher incidence among indigenous people. Albeit uncommon, autoimmune hemolytic anemia (AIHA) has been deemed a risk condition to develop mycobacterial infection, as a result of the immunosuppressive treatments. TB, in turn, can be a predisposing factor for secondary infections., Case Presentation: Here we present a case of a 28-year-old indigenous woman from Colombia, previously diagnosed with AIHA and pulmonary TB. Despite various treatments, therapies and medical interventions, the patient died after severe medullary aplasia of multiple causes, including secondary myelotoxicity by immunosuppressive therapy and secondary disseminated infections, underlining infection by Staphylococcus aureus, Klebsiella pneumoniae and Candida glabrata, which were identified as drug-resistant microorganisms. Together, this led to significant clinical complications. Invasive aspergillosis was diagnosed at autopsy., Conclusions: This report presents a rarely finding of AIHA followed by TB, and highlights the great challenges of dealing with co-infections, particularly by drug resistant pathogens. It also aims to spur governments and public health authorities to focus attention in the prevention, screening and management of TB, especially among vulnerable communities, such as indigenous people., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
45. Chronic Cavitary Pulmonary Aspergillosis: Complication of Pulmonary Tuberculosis.
- Author
-
Tiwari B, Adhikari S, Ghimire M, Singh S, and Kafle A
- Subjects
- Humans, Male, Adult, Chronic Disease, Antitubercular Agents therapeutic use, Antifungal Agents therapeutic use, Nepal, Tuberculosis, Pulmonary complications, Tuberculosis, Pulmonary drug therapy, Pulmonary Aspergillosis complications, Pulmonary Aspergillosis drug therapy
- Abstract
Pulmonary Aspergillosis is a fungal infection of the lungs that can lead to invasive disease and the formation of cavities, especially in the immunocompromised population. The most common clinical features are no symptoms at all to fever, cough, nondescript chest discomfort, trivial hemoptysis, and shortness of breath. Most patients respond well to Itraconazole therapy. Pulmonary Tuberculosis is one of the conditions that can lead to Aspergillosis, especially in cavities that are formed by Mycobacteria; both often manifest with similar clinical features and lead to diagnostic error. We present a case of a 28-year-old male diagnosed with pulmonary tuberculosis who developed symptoms of persistent cough, hemoptysis, increasing fatigue, and weight loss despite compliance with antitubercular therapy. Ultimately diagnosis of Cavitary pulmonary aspergillosis was made on clinical, laboratory, and radiological grounds. In a patient presenting with worsening symptoms of tuberculosis, there should be a suspicion of aspergillosis, necessitating the performance of standard fungal infection investigations. Keywords: Immunocompromise iosts; lung cavity; pulmonary aspergillosis; tuberculosis.
- Published
- 2024
- Full Text
- View/download PDF
46. Relationship of neutrophil lymphocyte ratio, monocyte lymphocyte ratio and neutrophil monocyte ratio with treatment response in pulmonary tuberculosis patients during intensive phase treatment.
- Author
-
Omair M, Baig MS, Farooqui WA, Kousar S, Noori MY, Zeehan N, Khan A, Isa S, Kamran DS, Bari MF, and Mehmood M
- Subjects
- Humans, Male, Female, Adult, Cross-Sectional Studies, Middle Aged, Treatment Outcome, Young Adult, Sputum microbiology, Adolescent, Rifampin therapeutic use, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary blood, Tuberculosis, Pulmonary microbiology, Neutrophils, Lymphocytes, Monocytes, Antitubercular Agents therapeutic use
- Abstract
Objective: To determine the relationship of Neutrophil Lymphocyte Ratio (NLR), Monocyte Lymphocyte Ratio (MLR), and Neutrophil Monocyte Ratio (NMR) with treatment response in Pulmonary Tuberculosis (PTB) patients during intensive phase treatment (IPT)., Methods: This analytical cross-sectional study was conducted at Ojha Institute of Chest Diseases (OICD), Dow University of Health Sciences, from February to December 2021. 100 patients were enrolled using purposive sampling technique. Both male and female of age 18 and above, rifampicin sensitive newly diagnosed cases of PTB by Acid Fast Bacilli (AFB) microscopy and Gene Xpert MTB/RIF were included. SPSS version 26 was used to analyze data. Numerical data was expressed in median and interquartile range and categorical data was expressed in frequencies and percentages., Results: Out of total 100 patients, 81% (n = 81) showed treatment response with negative AFB Sputum Smear Microscopy (SSM) after 2nd month. Out of 81% (n = 81) of the patients who achieved treatment response, 83.9% (n = 68) also had decreased NLR, 85.2% (n = 69) had decreased MLR and 83.9% (n = 68) had decreased NMR from baseline. However 19% (n = 19) did not achieved treatment response with positive AFB SSM after 2nd month of ATT (Anti tuberculosis treatment), among them 10.52% (n = 2) were INH resistant with no decrease in all the ratios after 2nd month., Conclusion: Leukocyte ratios decreased significantly from baseline as PTB was treated in patients who achieved treatment response with negative AFB SSM after two months of ATT and hence these ratios could be used as markers to monitor the treatment response., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
47. [Evaluation of molecular diagnosis of tuberculosis and resistance to rifampicin with GeneXpert ® MTB/RIF in Algeria].
- Author
-
Yamouni F, Henniche FZ, Ifticene M, Chabani M, Bensersa D, Ouadah NEH, Nihad M, and Zerouki A
- Subjects
- Humans, Algeria, Retrospective Studies, Female, Male, Adult, Middle Aged, Drug Resistance, Bacterial genetics, Young Adult, Tuberculosis diagnosis, Tuberculosis microbiology, Tuberculosis drug therapy, Molecular Diagnostic Techniques methods, Microbial Sensitivity Tests, Tuberculosis, Pulmonary diagnosis, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary microbiology, Aged, Adolescent, Tuberculosis, Multidrug-Resistant diagnosis, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Multidrug-Resistant microbiology, Sensitivity and Specificity, Rifampin pharmacology, Mycobacterium tuberculosis drug effects, Mycobacterium tuberculosis genetics, Antibiotics, Antitubercular pharmacology
- Abstract
Objective: 1) To evaluate the contribution of the GeneXpert
® MTB/RIF (GX) test in the diagnosis of pulmonary and extra-pulmonary tuberculosis compared to culture. 2) To compare the rifampicin results resistance obtained by GX with the phenotypic sensitivity test., Materials and Methods: Retrospective study carried out over a period of five years, from May 2017 to June 2022 at the microbiology laboratory of the Central army Hospital Mohamed Seghir Nekkache, Algiers (Algeria). The pulmonary and extrapulmonary clinical specimens were collected, cultivated, tested by GX PCR and direct examination by Ziehl-Neelsen staining. The study of sensitivity to antituberculosis drugs was performed according to the proportion method on liquid medium Bactec MGIT 960 (or on solid medium Lowenstein-Jensen at the Algerian Pasteur Institute)., Results: 310 samples were included in the final analysis of the study, of which 156 were of pulmonary origin and 154 of extrapulmonary origin. Mycobacterium tuberculosis complex (MTBC) was detected in 95 samples from 88 tuberculosis patients (sex ratio 2,03 and middle age 37 years) with 49 cases of pulmonary tuberculosis and 39 cases of extra-pulmonary tuberculosis. For 2 cases, the GX was positive while the culture was negative and for 11 cases, the GX was negative while the culture was positive. Thus, in our study and compared to culture, GX showed an overall sensitivity of 88.2%, a specificity of 98.6%, a positive predictive value (PPV) of 96.4% and a negative predictive value (NPV) of 95.2%. The analysis of the data according to the type of samples, the sensitivity, specificity, PPV and NPV of GX for the pulmonary and extrapulmonary samples were 96.3% vs. 77.0%, 98.0% vs. 99.1%, 96.2% vs. 96.5% and 98.0% vs. 92.7% respectively. The sensitivity of GX for disco-vertebral, lymph node, meningeal and pleural tuberculosis were 100%, 90.0%, 71.4% and 57.1% respectively. The sensitivity of GX for pulmonary tuberculosis compared to microscopy was 96% vs. 68%. The comparison of the results of detection of resistance to rifampicin by GX and by phenotypic methods showed perfect agreement., Discussion and Conclusion: A good sensitivity of GX compared to microscopy was revealed. The GX is a useful tool for the diagnosis of pulmonary tuberculosis, especially in smear-negative cases. The sensitivity of GX in extrapulmonary tuberculosis varied depending on the location of the infection. A negative result by GX does not exclude tuberculosis and cases of resistance to RIF detected by GX must be confirmed by phenotypic method., Competing Interests: Les auteurs n’ont aucun conflit d’intérêts à déclarer., (Copyright © 2024 SFMTSI.)- Published
- 2024
- Full Text
- View/download PDF
48. Impact of hyperglycemia on tuberculosis treatment outcomes: a cohort study.
- Author
-
Yanqiu X, Yang Y, Xiaoqing W, Zhixuan L, Kuan Z, Xin G, Bo Z, Jinyu W, Jing C, Yan M, and Aiguo M
- Subjects
- Humans, Female, Male, Middle Aged, Treatment Outcome, Adult, Cohort Studies, Antitubercular Agents therapeutic use, Aged, Blood Glucose metabolism, Blood Glucose analysis, Sputum microbiology, Hyperglycemia complications, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary complications
- Abstract
Hyperglycemia is prevalent and closely associated with pulmonary tuberculosis (PTB). This study aimed to investigate the effects of hyperglycemia on the outcomes of PTB treatment. This study comprised 791 patients with PTB in total. Patients with fasting plasma glucose levels of ≥ 6.1 mmol/L were diagnosed with hyperglycemia. Anthropometric and baseline demographic data were also collected. The treatment response was assessed based on clinical symptoms (sputum production, cough, chest pain, fever, hemoptysis, night sweats, loss of appetite, and fatigue), sputum smear, chest computed tomography (CT), and adverse gastrointestinal responses (vomiting, nausea, abdominal distension, diarrhea, and constipation). A generalized estimating equation (GEE) was used to evaluate these relationships. Hyperglycemia affected 266 (33.6%) of the 791 patients with PTB. In GEE analyses, patients with hyperglycemia exhibited a greater incidence of elevated tuberculosis (TB) scores (odds ratio (OR) 1.569; 95% CI 1.040-2.369), cough (OR 1.332; 95% CI 1.050-1.690), and night sweats (OR 1.694; 95% CI 1.288-2.335). Hyperglycemia was linked with a higher risk of positive sputum smears (OR 1.941; 95% CI 1.382-2.727). During therapy, hyperglycemia was also associated with an increased incidence of vomiting (OR 2.738; 95% CI 1.041-7.198), abdominal distension (OR 2.230; 95% CI 1.193-4.171), and constipation (OR 2.372; 95% CI 1.442-3.902). However, the CT results indicated that hyperglycemia did not affect pulmonary lesions in patients with TB. Patients with TB and hyperglycemia are at a higher risk of severe clinical manifestations, positive sputum smears, and adverse gastrointestinal effects and, therefore, the special situation of hyperglycemic patients should be considered in the prevention and treatment of TB., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
49. Artificial intelligence-based radiographic extent analysis to predict tuberculosis treatment outcomes: a multicenter cohort study.
- Author
-
Kim HJ, Kwak N, Yoon SH, Park N, Kim YR, Lee JH, Lee JY, Park Y, Kang YA, Kim S, Mok J, Kim JY, Jeon D, Lee JK, and Yim JJ
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Treatment Outcome, Aged, Adult, Mycobacterium tuberculosis drug effects, Mycobacterium tuberculosis isolation & purification, Rifampin therapeutic use, Republic of Korea, Tomography, X-Ray Computed methods, Antitubercular Agents therapeutic use, Radiography, Thoracic methods, Artificial Intelligence, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary diagnostic imaging, Sputum microbiology
- Abstract
Predicting outcomes in pulmonary tuberculosis is challenging despite effective treatments. This study aimed to identify factors influencing treatment success and culture conversion, focusing on artificial intelligence (AI)-based chest X-ray analysis and Xpert MTB/RIF assay cycle threshold (Ct) values. In this retrospective study across six South Korean referral centers (January 1 to December 31, 2019), we included adults with rifampicin-susceptible pulmonary tuberculosis confirmed by Xpert assay from sputum samples. We analyzed patient characteristics, AI-based tuberculosis extent scores from chest X-rays, and Xpert Ct values. Of 230 patients, 206 (89.6%) achieved treatment success. The median age was 61 years, predominantly male (76.1%). AI-based radiographic tuberculosis extent scores (median 7.5) significantly correlated with treatment success (odds ratio [OR] 0.938, 95% confidence interval [CI] 0.895-0.983) and culture conversion at 8 weeks (liquid medium: OR 0.911, 95% CI 0.853-0.973; solid medium: OR 0.910, 95% CI 0.850-0.973). Sputum smear positivity was 49.6%, with a median Ct of 26.2. However, Ct values did not significantly correlate with major treatment outcomes. AI-based radiographic scoring at diagnosis is a significant predictor of treatment success and culture conversion in pulmonary tuberculosis, underscoring its potential in personalized patient management., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
50. ED50 of ciprofol combined with sufentanil for fiberoptic bronchoscopy of different patient populations with pulmonary tuberculosis.
- Author
-
Pan M, Liu W, Zhang Z, Li T, and Xie W
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Dose-Response Relationship, Drug, Aged, Hypnotics and Sedatives administration & dosage, Young Adult, Drug Therapy, Combination, Bronchoscopy methods, Sufentanil administration & dosage, Tuberculosis, Pulmonary drug therapy, Fiber Optic Technology
- Abstract
Background: Ciprofol is a promising sedative. This study aims to explore the median effective dose (ED50) of ciprofol in inhibiting responses to fiberoptic bronchoscopy in patients with pulmonary tuberculosis (PTB) of different genders and ages when combined with 0.15 μg/kg sufentanil, and to evaluate its efficacy and safety, providing a reference for the rational use of ciprofol in clinical practice., Methods: PTB patients who underwent bronchoscopy examination and treatment at The Third People's Hospital of Changzhou between May 2023 and June 2023 were selected and divided into four groups using a stratified random method. All patients received intravenous injection of 0.15 μg/kg sufentanil followed by injection of the test dose of ciprofol according to Dixon's up-and-down method. The initial dose of ciprofol in all four groups was 0.4 mg/kg, with an adjacent ratio of 1:1.1. The next patient received a 10% increase in the dose of ciprofol if the previous patient in the same group experienced positive reactions such as choking cough, frowning, and body movements during the endoscopy. Otherwise, it was judged as a negative reaction, and the next patient received a 10% decrease in the dose of ciprofol. The transition from a positive reaction to a negative reaction was defined as a turning point, and the study of the group was terminated when seven turning points occurred. Hemodynamic parameters, oxygen saturation and adverse reactions were recorded at different time points in all groups. The Probit regression analysis method was used to calculate the ED50 of ciprofol in the four groups and compare between the groups., Results: The ED50 of ciprofol combined with 0.15 μg/kg sufentanil for bronchoscopy in the four groups were 0.465 mg/kg, 0.433 mg/kg, 0.420 mg/kg and 0.396 mg/kg, respectively., Conclusion: The ED50 of ciprofol used for fiberoptic bronchoscopy varied among PTB patients of different genders and ages., Trial Registration: The Chinese Clinical Trial Registry, ChiCTR2300071508, Registered on 17 May 2023., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.